Stockwinners Market Radar for March 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:36 EDT Domo CFO sells $970.5K in common stock - In a regulatory filing, Domo disclosed that its CFO Bruce Felt sold 20K shares of common stock on March 18, 2022 in a total transaction size of $970.5K.

19:14 EDT Apple says all services now operating normally following outages - Apple said that, following various outages and issues with many of its services, all of its services are now operating normally.

19:06 EDT Electronic Arts says 'EA Sports PGA Tour' out Spring 2023 - Electronic Arts said its upcoming golf video game "EA Sports PGA Tour" will be come out Spring 2023. Reference Link

18:51 EDT Global Water Resources director buys $116.5K in common stock - In a regulatory filing, Global Water Resources disclosed that its director Andrew Cohn bought 7.3K shares of common stock March 21, 2022 in a total transaction size of $116.5K.

18:10 EDT Aurora Cannabis to acquire Thrive Cannabis for $38M - Aurora Cannabis is pleased to announce today that the company has reached an agreement to acquire all of the issued and outstanding shares of TerraFarma, the parent company of Thrive Cannabis. The Transaction is based upon aggregate consideration of $38M payable in cash and Aurora common shares, plus two earnout amounts payable in Aurora Shares or cash, if applicable, based on Thrive achieving certain revenue targets within two years of closing of the Transaction. The Transaction is expected to strategically strengthen Aurora's position in the Canadian market by placing the Thrive team in charge of Aurora's Canadian recreational portfolio, advancing the shift in focus to innovative premium products including dried flower, pre-rolls, vapour products, and concentrates. The Transaction is expected to close, subject to customary closing conditions, in Aurora's fiscal Q4 2022. It is anticipated that the Transaction will provide immediate positive Adjusted EBITDA to Aurora, and support the company's path to Adjusted EBITDA profitability in the first half of fiscal 2023.

17:37 EDT Brown-Forman 'commends' Biden Administration for tariff agreement with U.K. - Brown-Forman issued this statement regarding the tariff agreement announced earlier. "Brown-Forman commends the Biden Administration for today's tariff agreement with the United Kingdom. As a result of the agreement, American whiskey will again enjoy tariff-free trade between the U.S. and the U.K. as of June 1, 2022. Today's announcement follows the removal of the EU's tariff on American whiskey on January 1, 2022. We would like to thank Commerce Secretary Gina Raimondo, Ambassador Katherine Tai, U.K. Secretary of State for International Trade Anne-Marie Trevelyan, U.K. International Trade Minister Penny Mordaunt, U.K. Ambassador to the U.S. Karen Pierce, and their teams, as well as lawmakers in the U.S. and in the U.K. for their efforts to achieve this positive outcome. As the leading producer of American whiskey, Brown-Forman appreciates the Administration's unwavering commitment to rebuilding the Transatlantic alliance. The removal of tariffs on American whiskey and other U.S. exports creates more opportunities for the continued international growth of our American-made products."

16:54 EDT Adobe expects quarterly sequential revenue, EPS growth in Q3 and Q4 - Sees Q2 tax rate 18.5%. Says as a result of the lower-than-expected deductions from stock-based compensation, now sees FY22 effective tax rate 18.5%. Says seeing strong traffic, millions of monthly active users and high customer satisfaction in Creative Cloud Express. Says explosive demand for video content shows no signs of abating. Says seeing tremendous interest for Substance 3D and new 3D Modeler beta. Comments taken from Q1 investor presentation slides.

16:37 EDT Poshmark falls 6% to $13.00 after Q4 earnings miss and below-consensus guidance

16:31 EDT SiteOne Landscape acquires JK Enterprise Landscape Supply - SiteOne Landscape Supply announced its acquisition of JK Enterprise Landscape Supply, with seven locations in Northern Virginia and Maryland. JK Enterprise supplies bulk and bagged mulches and soil, hardscapes and nursery products to professional contractors and local government entities.

16:26 EDT Root appoints Rob Bateman as CFO - Root, announced the addition of Rob Bateman to join the company as its new CFO, effective April 11. Bateman joins Root as CFO with over two decades of broad strategic, financial and operational experience across the insurance industry, most recently as president and CFO of Ategrity Specialty Insurance Company.

16:20 EDT OraSure appoints Nancy Gagliano as interim CEO - OraSure announced that its board of directors has appointed Nancy Gagliano to serve as interim CEO, effective April 1. Gagliano is not a candidate for the permanent CEO position. As previously announced, Stephen Tang, president and CEO, will be the leaving the company as of March 31. The board's search for a permanent CEO is actively underway. On January 5, the company announced its intent to explore and evaluate a broad range of strategic alternatives, this board-led review is ongoing. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.

16:19 EDT Opera divests Nanobank stake to third-party buyer for $127.1M in cash - Opera Limited announced that it had sold its 42.35% ownership interest in NanoCred Cayman Co. Limited to an undisclosed thirdparty buyer for $127.1M in cash. Payment will be made in eight equal quarterly installments over the next two years with no contingencies. The transaction closed on March 22, 2022. The purchaser is a private equity investor with strong tech and consumer fintech experience. Opera obtained its ownership in Nanobank in August 2020 in exchange for contributing its emerging market fintech business to the newly established company. Opera's contributions, including cash and outstanding microloans, had a carrying value of $110.6M at the time, such that this divestment represents a gain realization of approximately $16.5M for Opera. The transaction will result in a recorded net loss equal to the difference between Opera's unaudited carrying amount of its investment in Nanobank of $176.4M at year-end 2021, and the present value of the $127.1M sales price.

16:16 EDT Exxon Mobil lead director Ken Frazier to retire, Jay Hooley to succeed - The board of directors of Exxon Mobil (XOM) said that lead independent director Kenneth Frazier has announced his intention not to stand for re-election to the board at the annual meeting of shareholders on May 25. Joseph (Jay) Hooley, former chairman and CEO of State Street (STT) and ExxonMobil director since 2020, has been selected by the independent directors to serve as lead director, effective after the annual meeting.

16:14 EDT Churchill Downs to acquire Chasers Poker Room in New Hampshire - Churchill Downs announced that it has signed a definitive agreement to acquire Chasers Poker Room in Salem, New Hampshire. Chasers is a gaming facility located approximately 30 minutes from downtown Boston that offers poker and a variety of table games. Since opening in 2017, Chasers has led all New Hampshire charitable gaming operators in both gaming revenue and local charitable contributions. In 2021, New Hampshire authorized existing charitable gaming operators to offer historical horse racing at licensed facilities. Following the closing of the acquisition, CDI plans to develop an expanded charitable gaming facility in Salem to accommodate historical racing machines. Upon closing, New Hampshire will be the fourth state in which CDI operates historical horse racing. CDI currently operates HRMs in Kentucky and will operate HRMs in Virginia and in Louisiana. Under New Hampshire law, a portion of revenue from charitable gaming operations is allocated to nonprofit organizations licensed in the state. The transaction is dependent on usual and customary closing conditions, including the company obtaining approvals from the New Hampshire Lottery Commission. The transaction is expected to close during the second quarter of 2022.

16:08 EDT Tailwind Two Acquisition shareholders approve Terran Orbital combination - Tailwind Two Acquisition Corp., a publicly traded special purpose acquisition company, today announced that shareholders of record as of February 4, 2022 approved the previously announced business combination with Terran Orbital Corporation, a small satellite manufacturer primarily serving the United States aerospace and defense industry, supported by over 94% of the shares of Tailwind Two voted at the extraordinary general meeting of shareholders held on March 22, 2022. Approximately 72% of total outstanding shares voted. Ten proposals were considered and voted upon by Tailwind Two's stockholders at the extraordinary general meeting, all of which were approved. The formal results of the vote will be included in a Current Report on Form 8-K to be filed by with the U.S. Securities and Exchange Commission by Tailwind Two. Pursuant to the Business Combination, at the closing, Terran Orbital will combine with Tailwind Two and the combined company's name will be Terran Orbital. Following the closing, Terran Orbital's common stock and warrants are expected to trade on the New York Stock Exchange under the ticker symbols "LLAP" and "LLAP WS," respectively. The business combination is expected to close on March 25, 2022.

16:06 EDT Novavax reports EUA in India for COVID-19 vaccine use in adolescents age12-18 - Novavax and Serum Institute of India announced that the Drugs Controller General of India, or DCGI, has granted emergency use authorization, or EUA, for Novavax' protein-based COVID-19 vaccine for adolescents aged greater than or equal to 12 to less than 18 years in India. The vaccine, also known as NVX-CoV2373, is manufactured and marketed in India by SII under the brand name Covovax and is the first protein-based vaccine authorized for use in this age group in India. A Phase 2/3, observer-blinded, randomized, controlled study in a total of 460 Indian adolescents aged greater than or equal to12 to less than18 years was conducted to evaluate the safety and immunogenicity of Covovax. The study demonstrated that Covovax was well-tolerated with a reassuring safety profile. Furthermore, the data indicated that Covovax is immunogenic in adolescents aged greater than or equal to12 to less than18 years. The authorization in India also references the ongoing PREVENT-19 pivotal Phase 3 pediatric expansion trial of NVX-CoV2373 in adolescents in the U.S. aged greater than or equal to12 to less than18, results of which were shared in February.

15:27 EDT D.C. mayor files lawsuit against Grubhub for hidden fees, deceptive tactics - The District of Columbia's Attorney General Karl A. Racine filed a lawsuit against Grubhub Holdings (JTKWY) for charging hidden fees and using deceptive marketing tactics during the heart of the COVID-19 pandemic to increase profits at the expense of consumers and local small businesses. "The Office of the Attorney General alleges that Grubhub's misleading practices harmed District residents who used its service, exploited local restaurants that were suffering during the pandemic, and violated consumer protection laws. OAG's lawsuit seeks to force Grubhub to end its deceptive marketing practices, be truthful about prices and fees, provide restitution to affected consumers, and pay penalties for violating District law. "Grubhub misled District residents and took advantage of local restaurants to boost its own profits, even as District consumers and small businesses struggled during the COVID-19 pandemic," said AG Racine. "Grubhub charged hidden fees and used bait-and-switch advertising tactics-which are illegal. On top of that, the company deceived users with a promotion that claimed to support local restaurants during the heart of the pandemic. But in reality, this program cut into struggling restaurants' profit margins while padding Grubhub's bottom line. Consumers don't mind paying for delivery fees, but Grubhub needs to be honest about those fees in the first place. With this lawsuit, we are seeking to force Grubhub to end its unlawful practices and be transparent so DC residents can make informed decisions about where to order food and how to support local businesses," said the statement, in part. Other companies in the food delivery space include DoorDash (DASH), Uber (UBER) and Lyft (LYFT). Reference Link

14:59 EDT Exxon Mobil appoints Dan Ammann President of Low Carbon Solutions - ExxonMobil (XOM) said that Dan Ammann, former General Motors (GM) president and CEO of Cruise autonomous vehicle company, has been appointed president of ExxonMobil Low Carbon Solutions, effective May 1. Ammann replaces Joe Blommaert, who has elected to retire after 35 years of service. Ammann was named CEO of Cruise, which is majority-owned by GM, in 2018, and was appointed president of GM in 2014. He was previously GM's chief financial officer and joined GM as treasurer in 2010. "We welcome Dan to ExxonMobil and will use his knowledge and experience to continue to build our Low Carbon Solutions business. I thank Joe for his contributions to the company's success and the significant progress made in developing our lower-emissions business. I wish Joe all the best in retirements," said Darren Woods, CEO and chairman of ExxonMobil.

14:19 EDT Adamis voluntarily recalling certain lots of Symjepi, FDA says - Adamis Pharmaceuticals is voluntarily recalling certain lots of Symjepi syringes to the consumer level due to the potential clogging of the needle preventing the dispensing of epinephrine, the FDA announced. Adamis has no received, or is aware of, any adverse events related to this recall, the agency added. Reference Link

14:04 EDT FreightCar America spikes higher after Q4 revenue up 23.8%, delivery view - Shares of FreightCar America are up $1.27 per share, or 29.19% to $5.63 after reporting Q4 results. Fourth quarter 2021 revenue of $75M was up 23.8% year-over-year, on deliveries of 604 railcars. Additionally, FreightCar America raised its 2022 delivery view to between 2,600 and 2,900 railcars, from its earlier view of between 2,350 and 2,650 railcars, versus 1,731 deliveries in fiscal 2021. Other companies in the U.S. freight rail space include Trinity Industries (TRN), Greenbrier (GBX), Wabtec (WAB), CSX (CSX) Union Pacific (UNP) and Norfolk Southern (NSC).

13:46 EDT McDonald's, Just Eat Takeaway announce new strategic partnership - McDonald's (MCD) and Just Eat Takeaway.com (JTKWY) have agreed to a new global strategic partnership, "evolving their existing local agreements to provide McDonald's customers and franchisees with the convenience and value of McDelivery in markets across the world." McDonald's and Just Eat Takeaway.com said the partnership will support growth of the McDelivery business and will lead to increased operational benefits for Just Eat Takeaway.com. The companies added, "This partnership will elevate existing local partnerships between Just Eat Takeaway.com and McDonalds, which will reduce complexity and provide great opportunity to innovate at scale together on operational efficiency and a seamless customer experience." Reference Link

13:15 EDT TotalEnergies to stop purchasing oil and petroleum products from Russia - TotalEnergies stated: "After the serious and unfounded accusations of "complicity in war crimes" leveled against TotalEnergies, the Company shares with its stakeholders its principles of conduct regarding its Russian related businesses in order to allow them understand how our Company is acting in a responsible manner. Considering the worsening conflict, TotalEnergies is also taking new steps. TotalEnergies reaffirms its firmest condemnation of Russia's military aggression against Ukraine, which has tragic consequences for the Ukrainian population and threatens peace in Europe. To act responsibly, as a European company and in accordance with its values, TotalEnergies has defined clear principles of conduct for managing its Russian related business... TotalEnergies is a minority shareholder in a number of non-state-owned Russian companies: Novatek (19.4%), Yamal LNG (20%), Arctic LNG 2 (10%) and TerNefteGaz (49%). These companies are managed by their own staff with a limited number of secondees from TotalEnergies. TotalEnergies is also a 20% partner in the Kharyaga joint venture operated by Zarubezhneft. The Company did indeed contribute to the construction phase of these companies' projects but has no activity or operational responsibility on those sites. TotalEnergies had only 11 secondees in these companies as of February 24, 2022, and only 3 seconded expatriates are in Russia as of today. TotalEnergies has thus initiated the gradual suspension of its activities in Russia, while assuring its teams' safety... TotalEnergies is a European energy company that must contribute to the supply security of the European continent, which does not have the same domestic resources as other western countries such as the United Kingdom or the United States. In accordance with the European Union's decisions to maintain at this stage Russian gas supplies, TotalEnergies continues to supply Europe with liquefied natural gas from the Yamal LNG plant within the framework of long-term contracts that it must honor as long as Europe's governments consider that Russian gas is necessary. Contrary to oil, it is apparent that Europe's gas logistics capacities make it difficult to refrain from importing Russian gas in the next two to three years without impacting the continent's energy supply. However, given the worsening situation in Ukraine and the existence of alternative sources for supplying Europe, TotalEnergies has unilaterally decided to no longer enter into or renew contracts to purchase Russian oil and petroleum products, in order to halt all its purchases of Russian oil and petroleum products as soon as possible and by the end of 2022 at the latest. TotalEnergies already announced that it halted all spot market trading since February 25, 2022, on Russian oil and petroleum products. This is also the case for spot trading transactions concerning Russian natural gas or liquefied natural gas. TotalEnergies has term contracts to purchase Russian oil and petroleum products that end, at the very latest, on December 31, 2022. These term contracts primarily cover supplies for the Leuna refinery in eastern Germany, which is served by the Druzhba pipeline from Russia. They also concern Europe's gasoil supply, which is short of this product (around 12% of Russian gasoil imports in Europe in 2021). In close cooperation with the German government, TotalEnergies will terminate its Russian oil supply contracts for the Leuna refinery as soon as possible and by the end of 2022 at the latest, and will put in place alternative solutions by importing oil via Poland. Already, a first contract will not be renewed at the end of March 2022. Concerning the gasoil shortfall in Europe, absent any instructions to the contrary from European governments, TotalEnergies will also terminate its Russian gasoil purchase contracts as soon as possible and by the end of 2022 at the latest. TotalEnergies will import petroleum products from other continents, notably its share of gasoil produced by the Satorp refinery in Saudi Arabia." Reference Link

13:02 EDT Insight selected to join Nvidia's DGX-Ready Managed Services program - Insight Enterprises (NSIT) announced that it is one of a select group of technology partners certified to support enterprises deploying NVIDIA (NVDA) DGX AI computing platforms under the new NVIDIA DGX-Ready Managed Services program. NVIDIA announced the program today at GTC, a global AI conference taking place online through March 24. NVIDIA DGX systems is an advanced computing platform for large-scale AI infrastructure. The new NVIDIA DGX-Ready Managed Services program gives clients the option to outsource management of DGX systems deployed in corporate data centers, including the implementation and monitoring of server, storage and networking resources required to support DGX platforms. "Enterprise-scale AI is becoming a cornerstone of business innovation and transformation, and that is fueling increasing adoption of NVIDIA DGX technology as part of the on-premises IT ecosystem," said Juan Orlandini, chief architect and distinguished engineer, Insight. "The new NVIDIA Managed Services program recognizes that overseeing the DGX environment requires specialized skills, and that many enterprises prefer to work with experienced service providers who can free their teams to focus on unlocking AI insights rather than spending time provisioning and maintaining their infrastructure platforms."

12:41 EDT Nvidia, Kroger announce strategic cooperation to reimagine shopping experiences - The Kroger Co. (KR) and NVIDIA (NVDA) announced a strategic collaboration to "reimagine the shopping experience using AI-enabled applications and services." Kroger and NVIDIA will build an AI lab and demonstration center to expand Kroger's freshness initiatives, improve shipping logistics and create a better shopping experience in stores through digital twin simulations. "Our collaboration with NVIDIA supports Kroger's 'Fresh for Everyone' commitment," said Wesley Rhodes, vice president of Technology Transformation & Research and Development at Kroger. "We look forward to learning more about how AI and data analytics will further our journey to provide our customers with anything, anytime, anywhere." The lab will be located in Kroger's Cincinnati-based headquarters office.

12:16 EDT Nvidia announces Lucid Group as new EV customer - NVIDIA (NVDA) announced the start of production of its NVIDIA DRIVE Orin autonomous vehicle computer, showcased new automakers adopting the NVIDIA DRIVE platform, and unveiled the next generation of its NVIDIA DRIVE Hyperion architecture at GTC. BYD and Lucid Group (LCID) announced they are adopting NVIDIA DRIVE for their next-generation fleets and the company also announced that its automotive pipeline has increased to over $11B over the next six years following a series of design wins. NVIDIA said: "More than 25 vehicle makers have adopted the NVIDIA DRIVE Orin system-on-a-chip, or SoC. Starting this year, they are introducing software-defined vehicles, built on the centralized AI compute platform. DRIVE Hyperion with NVIDIA Orin serves as the central nervous system and AI brain for new energy vehicles - delivering constantly improving, cutting-edge AI features while ensuring safe and secure driving capabilities."

12:00 EDT Gatos Silver falls -6.7% - Gatos Silver is down -6.7%, or -33c to $4.62.

12:00 EDT Rockley Photonics falls -9.4% - Rockley Photonics is down -9.4%, or -48c to $4.65.

12:00 EDT HireRight rises 21.5% - HireRight is up 21.5%, or $2.69 to $15.23.

11:58 EDT Nvidia launches Nvidia OVX computing system - NVIDIA today announced NVIDIA OVX, a computing system designed to power large-scale digital twins. NVIDIA OVX is purpose-built to operate complex digital twin simulations that will run within NVIDIA Omniverse, a real-time physically accurate world simulation and 3D design collaboration platform. The company said, "OVX will enable designers, engineers and planners to build physically accurate digital twins of buildings or create massive, true-to-reality simulated environments with precise time synchronization across physical and virtual worlds. Companies can evaluate and test complex systems and processes with multiple autonomous systems interacting in the same space-time to optimize, expand or create more efficient factories and warehouses or train robots and autonomous vehicles before deploying them in the physical world."

11:50 EDT Qualcomm, Square Enix partner over extended reality experiences - Qualcomm (QCOM) and Square Enix (SQNXF) yesterday announced a collaboration to explore extended reality, or XR, experiences for Square Enix's global network of game development studios and intellectual property. The Advanced Technology Division at Square Enix, will work on the Snapdragon Spaces XR Developer Platform and the two companies will collaborate on new paths to "push the boundaries of immersive gaming experiences." "Square Enix has always been committed to state-of-the-art game technology to push storytelling boundaries, delivering unforgettable experiences for our fans" said Ben Taylor, Technical Director, Square Enix Co., Ltd. "We have been investing in XR and look forward to building on Snapdragon Spaces. In particular, we think the time is right with XR to innovate on games of a classic genre we are especially known for and look forward to sharing them with the world to further our mission to help spread happiness across the globe." Reference Link

11:44 EDT Nvidia announces Grace CPU Superchip - NVIDIA announced its first Arm Neoverse-based discrete data center CPU designed for AI infrastructure and high performance computing. The NVIDIA Grace CPU Superchip comprises two CPU chips connected, coherently, over NVLink-C2C, a new high-speed, low-latency, chip-to-chip interconnect. The Grace CPU Superchip complements NVIDIA's first CPU-GPU integrated module, the Grace Hopper Superchip, announced last year, which is designed to serve giant-scale HPC and AI applications in conjunction with an NVIDIA Hopper architecture-based GPU. Both superchips share the same underlying CPU architecture, as well as the NVLink-C2C interconnect.

11:38 EDT Nintendo mobile game 'Dragalia Lost' to shut down - Nintendo said that the main campaign of its free-to-play mobile game "Dragalia Lost" is scheduled to reach its conclusion in July of 2022 with part two of chapter 26, the final and climactic addition to its long-running story. After the main campaign has concluded, service for the game itself will come to a close at a later date. Further details on the end-of-service schedule will be provided in a future notification. After the final set of new adventurers is added in a summon showcase scheduled for 03/31/2022 at 02:00, the game will not receive any new content updates aside from those for the main campaign and certain quests. The company noted that summon showcases for existing adventurers and dragons, as well as event revivals, will continue to be made available until service has ended. Reference Link

11:28 EDT Marriott signs agreement with Baraka to open luxury safari lodge in Africa - Marriott International has signed an agreement with Baraka Lodges LTD. to enter the safari segment in Africa. JW Marriott Masai Mara Lodge will be located within the Mara National Reserve, and the retreat expects to welcome guests in 2023, the company said in a statement.

11:01 EDT NetApp sees FY25E gross margin 69%-70% - Sees Public Cloud gross margin 75%-80% and Hybrid Cloud gross margin around 68%. Sees FY25 operating income over $2B, with operating cash flow also greater than $2B. Sees FY25 tax rate 21%-22%, and capital returns of 100% of FCF.

10:34 EDT Egan-Jones recommends Huntsman shareholders vote for Starboard nominees - Starboard Value LP, one of the largest shareholders of Huntsman Corporation, with an ownership stake of approximately 8.8% of the Company's outstanding shares, announced that Egan-Jones Proxy Services has recommended that Huntsman shareholders vote on Starboard's BLUE proxy card to elect all four of Starboard's nominees to the Huntsman Board of Directors at the Company's upcoming 2022 Annual Meeting of Shareholders. Egan-Jones' recommendation, combined with an earlier recommendation from Institutional Shareholder Services to also vote on Starboard's BLUE proxy card, provides significant validation that further change is needed on Huntsman's Board. Egan-Jones concluded that shareholders should vote on Starboard's BLUE proxy card saying: "After reviewing the merits of the Starboard solicitation, we believe that the dissident shareholders have made a compelling case for us to recommend for its nominees [...] We believe that the Starboard Nominees will bring the change that the Company needs. With strong backgrounds and experience in operations, finance, private equity, restructuring, strategic transformation, and public company governance, we strongly believe that James L. Gallogly, Sandra Beach Lin, Susan C. Schnabel, and Jeffrey C. Smith will collectively work towards the restoration of Huntsman's image to be one of the leaders in the chemical industry."

10:12 EDT Vor Bio, Akron BioProducts to develop cGMP nucleases - Akron BioProducts and Vor Bio announced an agreement to develop and manufacture cGMP nucleases. "This collaboration strengthens Akron's portfolio of off-the-shelf gene editing technologies while broadening Vor Bio's collection of nucleases to engineer gene modified cell therapies. Vor Bio continues to strategically invest in its proprietary manufacturing capabilities for its engineered HSC and CAR-T programs. The companies will collaborate in the development and manufacture of starting materials needed to advance potentially transformative treatments for blood cancers into the clinic," the press release reads.

10:08 EDT Turtle Beach jumps 6% to $20.73 after Citron Research tweet

10:03 EDT Unity Software appoints Michelle Lee to board of directors - Unity Software announced the appointment of Michelle Lee, former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, to the company's Board of Directors. As part of her Board appointment, Ms. Lee will also serve on the Audit Committee of the Board.

10:01 EDT UMass Chan Medical School announces research collaboration with Moderna - UMass Chan Medical School announced a research collaboration with Moderna on a comprehensive study of cytomegalovirus transmission in group childcare, education, and household settings. The study, called CMV Transmission and Immune Tracking, will examine how CMV spreads among children and between household members, with an aim to characterize immune responses to CMV infection over time. Findings from the study will inform the design of CMV prevention strategies, including awareness campaigns for CMV, to reduce its spread in similar group settings, according to a statement.

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -5.4% - ProShares UltraShort Bloomberg Natural Gas is down -5.4%, or -$1.16 to $20.15.

10:00 EDT Dingdong rises 12.0% - Dingdong is up 12.0%, or 41c to $3.83.

10:00 EDT HireRight rises 23.3% - HireRight is up 23.3%, or $2.92 to $15.46.

09:55 EDT Biotricity to launch commerical sales of Biotres in April - Biotricity will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022. The Company has plans to roll out additional complementary products throughout 2022, following the same approach as Biotres. Each solution will grow the company's TAM, creating new revenue streams for existing customers while expanding its customer base.

09:47 EDT Vince Holding falls -3.8% - Vince Holding is down -3.8%, or -30c to $7.70.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -5.7% - ProShares UltraShort Bloomberg Natural Gas is down -5.7%, or -$1.21 to $20.10.

09:47 EDT Zhihu rises 16.2% - Zhihu is up 16.2%, or 42c to $3.02.

09:37 EDT JX Luxventure signs $60M sales agreement with Chongqing E-Pet - JX Luxventure announced that, on March 21, 2022, Jin Xuan Luxury Tourism Digital Technology entered into and executed a Framework Agreement on Strategic Cooperation with Chongqing E-Pet Technology. Pursuant to the Agreement, Chongqing E-Pet will purchase from JX Hainan cross-border pet foods in the amount up to $60,000,000 to be distributed on the platforms operated by Chongqing E-Pet.

09:30 EDT Statera BioPharma announces pricing of $5.7M underwritten public offering - Statera Biopharma announced the pricing of its underwritten public offering of approximately 10,843,721 units, at a price to the public of $0.45 per Unit and approximately 1,716,666 pre-funded units, at a price to the public of $0.44 per Pre-Funded Unit, for aggregate gross proceeds of approximately $5.7 million, prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Each Unit consists of one share of common stock, par value $0.005 per share, one warrant with a one-year term to purchase one share of Common Stock at an exercise price of $0.45 per share, and one warrant with a five-year term to purchase one share of our Common Stock at an exercise price of $0.5625 per share. The shares of Common Stock, the One-Year Warrants, and the Five-Year Warrants are immediately separable and will be issued separately and uncertificated. Each Pre-Funded Unit will consist of one pre-funded warrant to purchase one share of Common Stock, one One-Year Warrant, and one Five-Year Warrant. The purchase price of each Pre-Funded Unit will equal the price per Unit being sold to the public in this offering, minus $0.01, and the exercise price of each Pre-Funded Warrant will equal $0.01 per share of Common Stock. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,884,057 shares of Common Stock, and/or One-Year Warrants to purchase 1,884,057 shares of Common Stock and/or Five-Year Warrants to purchase 1,884,057 shares of Common Stock at the public offering price of $0.44 per share, $0.01 per One-Year Warrant and $0.01 per Five-Year Warrant, less the underwriting discount per share and per warrant, solely to cover over-allotments, if any. The offering is expected to close on or about March 24, 2022, subject to satisfaction of customary closing conditions. EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.

09:28 EDT TOP Ships announces compliance with Nasdaq bid price requirement - TOP Ships announced that NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement for the Nasdaq Capital Market, set forth in Nasdaq Listing Rule 5550(a)(2).

09:26 EDT Diana Shipping announces time charter contract for M/V New Orleans - Diana Shipping has entered into a time charter contract with Engelhart CTP Freight SA, for one of its Capesize dry bulk vessels, the m/v New Orleans. The gross charter rate is $32,000 per day, minus a 5% commission paid to third parties, for a period until minimum November 20, 2023 up to maximum January 31, 2024. The charter is expected to commence on March 25, 2022. The m/v New Orleans is currently chartered, as previously announced, to Nippon Yusen Kabushiki Kaisha, at a gross charter rate of US$15,500 per day, minus a 5% commission paid to third parties. The "New Orleans" is a 180,960 dwt Capesize dry bulk vessel built in 2015. The employment of "New Orleans" is anticipated to generate approximately $19.04 million of gross revenue for the minimum scheduled period of the time charter.

09:23 EDT Philips, Nuvo team to extend prenatal care delivery starting in rural Colorado - Royal Philips and Nuvo Group, a private company commercializing INVU by Nuvo an FDA-cleared, prescription-initiated, remote pregnancy monitoring platform, today announced a collaboration to develop a more inclusive pregnancy care experience from the prenatal stage through labor and delivery. Through the collaboration, Philips will support Nuvo in facilitating remote fetal monitoring pilot programs that focus on increasing access and adherence to prescribed care in remote areas, beginning with a pilot program in rural Colorado. More than half of the counties in the USA offer very limited or no access to maternity care [1]. Within these counties, more than 2.2 million women of childbearing age live in full maternity care deserts, which have no hospital offering obstetric care, no birth center, and no obstetric provider [2]. Following the recent White House call to action for organizations to help improve health outcomes for parents and infants, Philips and Nuvo will collaborate to pilot Nuvo's INVU pregnancy monitoring system as part of an integrated solution for rural care providers and their patients in the USA. "Digital solutions and ecosystem-building are critical enablers to addressing disparities in healthcare such as access to maternal health care in rural settings," said Sandra Lesenfants, General Manager Hospital Patient Monitoring at Philips. "With this collaboration, we are extending the sight and reach of pregnancy care and bringing more remote monitoring options to the communities and expectant mothers where and when they need them most." The USA continues to experience acute staffing shortages in medical care - a challenge common in rural areas long before the COVID-19 pandemic. This initiative has the potential to help ease the burden on providers by shifting a portion of care to the home setting. Providers will be able to prescribe INVU to expectant mothers, who will wear the sensor band during virtual visits with their physicians. During these visits, a live reading allows the expectant mother to access simplified data and insights via the paired INVU app, while the provider receives NST readings comparable to deeper fetal surveillance that OB/GYNs are accustomed to receiving during in-office procedures.

09:22 EDT Carnival provides update on bookings - CEO Donald added, "Given the recent strengthening in booking volumes coupled with the closer-in booking patterns, we expect an extended wave season. In fact, we gained occupancy even in the month of March with fleetwide occupancy nearing 70 percent and several sailings already exceeding 100 percent." Since the middle of January, the company has seen an improving trend in weekly booking volumes for future sailings. Recent weekly booking volumes have been higher than at any point since the restart of guest cruise operations. During the first quarter, the company increased its booked occupancy position for the second half of 2022, albeit not at the same pace as a typical wave season due to the Omicron variant. As a result, cumulative advance bookings for the second half of 2022 are at the lower-end of the historical range. However, the company believes it is well situated with its current second half 2022 booked position given the recent improvements in booking volumes and its continued expectation that occupancy will build throughout 2022 and return to historical levels in 2023. Normalized for bundled packages, prices on bookings for the second half of 2022 continue to be higher, with or without future cruise credits, as compared to 2019 sailings. Cumulative advanced bookings for the first half of 2023 continues to be both at the higher end of the historical range and at higher prices, with or without FCCs, normalized for bundled packages, as compared to 2019 sailings. Total customer deposits increased to $3.7B as of February 28, 2022 from $3.5B as of November 30, 2021.

09:21 EDT Qualigen Therapeutics announces three published abstracts at AACR - Qualigen Therapeutic provides data from published abstracts from the American Association of Cancer Research, AACR, demonstrating positive in vivo data on the Company's lead compound QN-302. QN-302 is the Company's genomic quadruplex-selective transcription inhibitor being developed as a potential treatment for pancreatic ductal adenocarcinoma, PDAC, in addition to other tumors of high unmet clinical need. The abstracts accepted by AACR outline the potential binding to a quadruplex target for the compound, as well as significant anti-tumor activity in relevant animal models. "The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer." This abstract reports that QN-302 showed significant anti-tumor activity in three patient-derived xenograft models for pancreatic ductal adenocarcinoma. This supports the hypothesis that the mechanism of action of QN-302 in vivo involves targeting of quadruplex-containing genes, which is also corroborated by the PDX data since these tumors have elevated levels of several quadruplex-containing genes previously identified in cells and in vivo. "The potent quadruplex-binding compound SOP 1812 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer." In this study, the authors evaluated the activity of QN-302 in the PC3 xenograft model using a twice-weekly 1 mg/kg dose regimen intravenously administered against control and the established prostate cancer drug abiraterone, at a daily dose of 200 mg/kg, administered by the oral route, both over a 28-day period. The study authors concluded that QN-302 was bio-available at therapeutic doses and was well tolerated at these levels in this animal model. "Structure-based design of quadruplex-binding small molecule compounds: The essential role of water molecules," describes the design of the compound QN-302 targeted against human DNA quadruplexes by means of computer modelling. The abstract further describes the optimization of an existing naphthalene diimide compound leading to QN-302, which has single-digit 1-20 nM anti-proliferative activity in a panel of human pancreatic ductal adenocarcinoma cell lines.

09:20 EDT Vivakor collaborates with TBT, CREATEs on prototyping of roadway sensors - Vivakor announced that in collaboration with TBT Group, Inc. and the Center for Research and Education in Advanced Transportations Systems at Rowan University, the completion of the design stages of its self-powered roadway sensors and the beginning of prototype stages. Four types of smart road sensors have been designed: one to collect temperature data to allow Departments of Transportation to better direct salting and plowing operations; one to collect roadway wear information to better direct repair crews; one to detect traffic; and one to communicate directly with smart automobiles, providing them a clear picture of the edge of the highway, as weather, daylight and other conditions can have negative effects on the onboard automobile sensors. The sensors utilize TBT's energy harvesting piezo-electric technology which converts the traffic-induced vibrations of the roadway to energy that powers the embedded sensors; eliminating the need for battery replacement or costly maintenance and allowing for the low-cost and easy-to-install smart sensors to be sustainable far beyond the roadway lifetime.

09:19 EDT Cue Health and Albertsons announce partnership - Cue Health (HLTH) and Albertsons (ACI) announced a first-of-its-kind partnership that offers customers access to Cue's highly accurate, convenient, and fast molecular COVID-19 tests at participating Albertsons Cos. pharmacies across the country. Pharmacy personnel will provide this new service, which will allow customers to get Cue's lab-quality COVID-19 test results delivered to their email in 20 minutes. Albertsons Cos. and Cue piloted this in-pharmacy COVID-19 testing program last fall in 40 pharmacies in the state of Washington and at Lumen Field for fans attending Seattle Seahawks home games. The companies have since rolled out the offering into approximately 900 pharmacies and expect the test to be available at most Albertsons Cos. pharmacies over the coming weeks. Cue's COVID-19 test is currently being used in point-of-care settings across the country and is authorized for at-home use as well, with data showing that it is the most accurate self-test for COVID-19.

09:18 EDT Matterport announces Damen Shipyard uses Matterport Digital Twins - Matterport announced that Damen Shipyards Group, a Dutch-owned shipbuilding company, has adopted Matterport digital twins to facilitate remote collaboration for internal and external stakeholders. Across its Workboat Division, including its major shipyards in China, Turkey and Vietnam, Damen uses Matterport Pro2 3D cameras to capture digital twins of its vessels. With access to a 3D space in the planning stage, customers can examine the layout and placement of equipment and request modifications if desired. In addition, the Measurement Mode capability within a Matterport digital twin allows Damen's design and engineering personnel to verify measurements down to the centimeter. "The growing adoption of Matterport across several industries, from store management to commercial boats, demonstrates that digital twins add operational efficiency and engage customers throughout their journeys," said Conway Chen, VP of Business Development and Strategy at Matterport. "With Matterport digital twins at their fingertips, Damen is able to further advance its reputation as a technology-driven organization focused on providing the best experience for its customers."

09:17 EDT Laurentian Bank enters partnership with thirdstream - Laurentian Bank of Canada announced it is partnering with Canadian-based thirdstream to bring its digital account opening solutions to market. The strategic partnership will enable the Bank's existing and new customers the ability to open accounts anywhere, anytime, and from any device. Customers will use a simplified, fully digital application process to open accounts, often in under five minutes. Built on its Application Programming Interface platform, thirdstream's identity verification capability rapidly integrates over 25 identity verification fraud management and account funding solutions into a single unified identity verification ecosystem and experience. thirdstream's platform will help Laurentian Bank offer seamless and efficient customer experiences, helping the Bank deliver the products and services designed to meet the needs of Canadian consumers. Scheduled to deploy later in 2022, the customer experience will include fraud prevention, identity verification, automated decisioning, real-time account funding, and document management.

09:17 EDT EzFill signs fleet fueling agreement with 911 Restoration of Miami - EzFill announced a new fleet agreement with 911 Restoration of Miami, effective immediately. EzFill will provide regular mobile fuel delivery service for 911 Restoration, which is part of a nationwide franchise providing water damage and fire damage restoration, mold and smoke removal, and all other property disaster services. Its water damage team is available 24 hours a day for emergencies. "When area residents turn to 911 Restoration for help with water damage and other property disasters, the company's drivers need to be ready to respond as quickly as possible. Our regularly scheduled mobile fueling ensures their fleet of vans will always be filled up and ready to act quickly in an emergency, no matter when they get the call," said Mike McConnell, CEO of EzFill. "Our service also eliminates the time and fuel wasted driving to and from local gas stations instead of helping customers."

09:16 EDT RealReal provides long-range financial targets for FY25 - The RealReal announced its Vision 2025 financial targets and will host its Investor Day later. "We are pleased to host our Investor Day at our Phoenix Authentication Center and showcase many of our technology innovations across our operations, including authentication and dynamic pricing. We look forward to discussing in-depth our long-range financial targets, which we are referring to as Vision 2025," said Julie Wainwright, founder and CEO of The RealReal. Vision 2025 Long-Range Financial Targets for Full Year 2025: Based on market conditions as of March 22, 2022, the company is providing long-term targets for GMV, Total Revenue and Adjusted EBITDA, which is a Non-GAAP financial measure. GMV of $5.0+B. Total Revenue of $1.5B+. Adjusted EBITDA of $100M+.

09:13 EDT Intapp announces WAM selected DealCloud - Intapp announced that Women's World Banking Asset Management, WAM, the investment arm of Women's World Banking, has selected DealCloud to enhance pipeline and portfolio management, investor relations, and reporting. "We're beyond excited to be working with Women's World Banking," said Ben Harrison, President of Financial Services at Intapp. "We believe the DealCloud platform will help Women's World Banking Asset Management and its portfolio companies continue to develop innovative financial products and services that will make a meaningful impact for women, their families, and their communities in the emerging markets."

09:13 EDT Verizon Business announces capabilities for BlueJeans Mobile for Android, iOS - At Enterprise Connect, Verizon Business announced new capabilities for BlueJeans Mobile for Android and iOS and new as-a-service packaging options for BlueJeans Rooms. Delivering a new set of functionality across work modes-office, home, or remote/field-the latest updates to the BlueJeans platform were designed to support the workflow consistency and inclusivity teams need to be productive in today's anytime, anywhere work environment. Zero-Touch Conference Room Access: Working on legacy standards-based endpoints and the new Android-based experience for BlueJeans Rooms, meeting participants will be able to use their mobile device to start and control meetings running on their conference room systems. Using a new pairing code on the in-room monitor and a new Pair with Room button in the mobile app, the mobile user can join a meeting through the mobile app and then control the experience with audio/video controls. Once paired, the meeting room calendar will also be synced to the mobile user's calendar. Enhancements such as chat and raise hand will help to foster inclusiveness, while users on the move will appreciate Meeting Shift, where a mobile user auto pairs with a conference room in-meeting and moves the meeting to the room using the same Pair with Room workflow. Mobile Collaboration with Collab Board: Further enabling meeting equity for remote attendees, iOS and Android users can now access the BlueJeans Collaboration Board on their mobile device. With simultaneous co-creation for up to 25 users, Collab Board provides an integrated, infinite canvas for brainstorming collaboration that is just a simple click away.

09:11 EDT Verisk Analytics announces updates for Ready for Guidewire accelerators - Insurers, self-insureds and Third Party Administrators can now more easily fulfill their Section 111 Medicare reporting compliance requirements with Ready for Guidewire accelerators from Verisk. The newest updates for Guidewire customers include Provide Accurate Information Directly Act data, which offers visibility into claimants' participation in a Medicare Advantage Plan. The PAID Act provides insurers with 150 new data points which may be extremely time-consuming to manually sort through. Verisk's integrated PAID Act enhancements feature a new tab that displays which claimants are enrolled in MAP Part C or D.

09:11 EDT AvePoint announces enhancements to Cloud Records - AvePoint announced enhancements to Cloud Records, its SaaS platform designed to help organizations improve information lifecycle management and ensure data resilience and compliance. "The updates to Cloud Records give organizations better control over their electronic and physical records, effectively managing their content through lifecycle outcomes from creation, to classification, and retention or disposal, in one centralized SaaS platform," the company said. To help organizations manage the lifecycle of their information the following updates to Cloud Records have been made: More complex search functionality; Delegated administration; and Additional content sources. AvePoint helps securely streamline the information lifecycle management for hundreds of organizations, many of which are in regulated industries, like the IRS, Cancer Council, Airways New Zealand, and the Australian Transport Safety Bureau, who chose to sponsor AvePoint's IRAP Assessment in Australia.

09:09 EDT NMI Holdings releases 2022 sustainability report - NMI Holdings released its 2022 Sustainability Report, highlighting the company's continuing efforts across environmental, social and governance matters. Adam Pollitzer, President and Chief Executive Officer, said, "At National MI, we strive to be a sustainable, responsible organization - one that aims to make a difference in our communities and act with integrity at all times. Our social mission is anchored in our commitment to supporting affordable and sustainable homeownership, and in the process accelerating financial inclusion for all communities. This report highlights our best practices and successes across key ESG matters relevant to our business, including the support we provide to aspiring homeowners, the investments we make in our people and communities, the work we do to advance diversity, equity and inclusion initiatives, and the focus we bring to governance and corporate responsibility."

09:08 EDT Gevo to supply Delta Air Lines with 75M gallons of SAF per year for seven year - Gevo (GEVO) has signed a "take-or-pay" agreement with Delta Air Lines (DAL) to supply 75M gallons of sustainable aviation fuel, SAF, per year for seven years. Based on current assumptions, including those around future pricing of commodities and the future values of certain environmental benefits, Gevo estimates that the Agreement should generate approximately $2.8B of revenue, inclusive of the value from environmental benefits, for Gevo over the seven-year term of the Agreement. "On behalf of the entire team at Gevo, I want to congratulate our partners at Delta for their leadership in continuously pushing the aviation industry towards net-zero emissions. Delta makes for a great customer, recognizing that big change is needed. I also appreciate their faith in what we are doing at Gevo. Net-zero jet fuels matter. We expect production from our first Net-Zero plant to begin in 2025. To meet the demand that we now have under contract, we need to develop and build more than one Net-Zero plant. This is a happy problem to have," said Patrick R. Gruber, Ph.D., Gevo's Chief Executive Officer. The Agreement is subject to certain conditions precedent, including Gevo developing, financing and constructing one or more production facilities to produce the SAF contemplated by the Agreement. A copy of the Agreement between Delta and Gevo has been filed with the U.S. Securities and Exchange Commission on Form 8-K.

09:08 EDT WISeKey offers two-factor authentication to mitigate cybersecurity risks - WISeKey International announced the offering of a two-factor authentication, allowing subscribers to replace their username and password login process with 2FA as a stronger method of protecting access to PCs and laptops and introducing stronger authentication before allowing access to emails and critical applications. WISeID, based on the WISeKey/OISTE Root of Trust, integrates innovative technologies to offer any individual or business entity, the ability to create an account, accessing several basic services, free of charge, which then can be upgraded to access additional multiple cybersecurity services. The WISeID web services and mobile applications, already available for download and use, provide users with a digital identity that can be used to secure email communication, digitally sign documents with legal validity and is complemented with features such as dual factor authentication and single sign-on.

09:07 EDT Nuvei supports new browser extension wallet XDCPay - Nuvei announces it has strengthened its integration with XDC Network, the global open-source Hybrid Blockchain platform, via its integration with XDC Foundation's Web3 browser extension wallet, XDCPay. "The XDCPay browser extension wallet grants easy access to Web3 and the world of decentralized finance, including XDC Network's own decentralized apps, to developers & XDC users," the company said. This latest integration with XDC Network's new browser plugin will allow users to buy XDC within the XDCPay wallet. "Our support of XDC Foundation's new wallet, XDCPay, is an important milestone in democratizing access to decentralized finance and allowing easy entry into the XDC Ecosystem to developers, traders and content creators," said Nuvei Chair and CEO Philip Fayer.

09:06 EDT PureCycle Technologies director buys $10M in common stock - In a regulatory filing, PureCycle Technologies disclosed that its director Timothy Glockner bought 1.43M shares of common stock on March 17th in a total transaction size of $10M.

09:04 EDT Mercury Systems announces RFS1140 SiP - Mercury Systems announced the new RFS1140 System-in-Package, a first to combine powerful FPGA processing with Jariet Technologies' high-speed data converters at chip scale and manufactured in a trusted U.S. microelectronics facility. By delivering the latest commercially developed integrated circuits, Mercury's SiP devices revolutionize edge processing applications by maximizing performance in a trusted, highly customizable architecture. "In the fall of 2019 Mercury announced a $15 million strategic investment in trusted microelectronics technology innovation," said Tom Smelker, vice president, Mercury Systems. "Our new RFS1140 is our latest product supporting that investment. By combining high-speed data converters, digital processing, memory and power in a single package, Mercury lowers overall system costs and complexity, and enables placement closer to the sensor edge, reducing latency. In addition, our trusted onshore design, manufacturing and testing directly support DoD requirements for critical state-of-the-art microelectronics."

09:03 EDT Datasea announces business cooperation agreement with Unicorner - Datasea announced that it has entered into a one-year business cooperation agreement with Unicorner, a company that possesses the comparative advantages on supply chain management such as procurement, logistic, warehousing, marketing, and sales on the sterilization industry in the United States and serves customers such as AT&T, Staple, Marriott, CVS, and Walgreen. The new partnership leverages the respective strengths of Datasea and Unicorner to create compelling value for both companies. Datasea will provide various acoustic intelligence products and technical support to Unicorner. Unicorner will utilize and share its over twenty years of experience in U.S. operations and internal expertise and external resources to help Datasea expand product distribution primarily in the U.S. market.

09:02 EDT Kore Group promotes Paul Holtz to CFO - KORE Group Holdings announced that Paul Holtz, who had been serving as the Company's interim CFO has been named KORE's Executive Vice President, CFO and Treasurer. Holtz has been serving as interim CFO since November 2021. He joined KORE in March 2017 and holds extensive public company experience in the technology and SaaS space. Mr. Holtz's role at KORE has been integral to the Company's focus on service delivery and the optimization of financial performance. Prior to joining KORE, Holtz served in various roles at Blackberry, most recently as Head of Finance for the office of the COO. Holtz received his bachelor's degree in Business Administration and Accounting from Wilfrid Laurier University. He is also a member of the Chartered Professional Accountants of Canada.

08:55 EDT Lazydays announces new dealership locations in Arizona and Ohio - Lazydays, The RV Authority, announces new dealership locations in Surprise, Arizona to serve the western Phoenix metropolitan area, and Wilmington, Ohio which is strategically located between the Columbus, Cincinnati, and Dayton metropolitan areas. The Company expects the new dealerships to open in the second quarter of 2023. The dealerships will be branded Lazydays RV of West Phoenix and Lazydays RV of Ohio. The Surprise dealership will be located off Arizona State Route 303 and brands will include Newmar, Coachmen, Thor and Forest River; and the Wilmington dealership will be located off Interstate 71.

08:49 EDT Itron, Duke Energy Florida collaborate to deploy DER Optimizer solution - Itron (ITRI) and Duke Energy Florida (DUK), which supplies electrical services to 1.9M customers throughout Florida, are collaborating to deploy Itron's newly developed DER Optimizer solution. Itron is expanding its IntelliSOURCE platform to be the foundation of a broader distributed energy resource management solution set, in recognition of the rapidly evolving landscape of DERs that utilities need to monitor, optimize and orchestrate to maintain grid reliability and safety and meet decarbonization goals. The DER Optimizer solution is a suite of modules that enables utilities to monitor residential electric vehicle, or EV, charging and manage holistic residential EV charging programs at scale. The program will begin in Q1 2022 and run for four years. During that time, Duke Energy Florida will use Itron's DER Optimizer to collect permissible EV charging session data in near-real time and gain insights into residential EV charging behavior.

08:49 EDT Helbiz launches live monthly subscription platform on Amazon Prime Video - Helbiz Media (HLBZ) announced that Helbiz Live will be available on Amazon (AMZN) Prime Video Channels on April 2nd, following the recently completed technology integration. A Helbiz Live monthly subscription featuring all content will be available for purchase on all devices and TVs with Amazon Prime Video. Fans of the Serie B Championship will be able to easily watch all the matches of the regular season and playoffs/playouts ive and on demand for the current and following two seasons. The subscription also features access to MLB and NCAA games and has been the streaming service for special events such as Miss Italia. This agreement will make Helbiz Live more accessible for customers by expanding the devices and methods they are able to use "This agreement is a great achievement and in recent months we have worked closely with the Amazon technical team to better prepare for the launch and to ensure that our subscribers receive the highest level of service. The partnership with Amazon Video is a very important step for Helbiz Live - it will contribute to a greater diffusion and distribution of our platform, while also enriching the range of sports-related content on Amazon Video, such as the recent agreement with Major League Baseball for the broadcasting of baseball games. As always, we work alongside our customers, and this agreement stems from the need to make the Helbiz Live service even more easily accessible and affordable." said Matteo Mammi, CEO of Helbiz Media.

08:46 EDT Baozun announces repurchase of $166.3M of convertible senior notes - Baozun announced that it has repurchased approximately $166.3 million principal amount of 1.625% Convertible Senior Notes due 2024, with Notes in the principal amount of approximately $108.7 million remaining outstanding after such repurchase.

08:45 EDT Sigma Labs, AMFG announce collaboration for additive manufacturing workflow - Sigma Labs announced that it has signed an agreement with AMFG to expand the footprint of both companies' solutions and provide the marketplace with an optimized AM solution that increases quality and efficiency while decreasing the costs of serial production. Specifically, the combination of the MES and in situ monitoring systems will allow AMFG and Sigma Labs users and OEM companies to: Automate full production workflow, including key visibility into production monitoring, with full traceability from powder to part. Move towards automated part and process qualification. View data in real-time, with ability to dive deep into analytics feed. Capture data to support simulation, material properties prediction and final pedigree, and key quality assurance checks to decrease post inspection needs. Provide data connectivity and integrity throughout the manufacturing process agnostic of equipment environment.

08:41 EDT Integra LifeSciences launches NeuraGen 3D Nerve Guide Matrix - Integra LifeSciences announced the launch of NeuraGen 3D Nerve Guide Matrix, a resorbable implant for the repair of peripheral nerve discontinuities. NeuraGen 3D is a nerve repair product specifically engineered to create an optimized environment that may allow for a more complete functional recovery following mid-gap nerve repair when compared to hollow nerve conduits alone. "The launch of NeuraGen 3D is a culmination of many years of research and a testament to the ongoing work of countless scientists and health care practitioners to develop cutting-edge solutions for the treatment of peripheral nerve injuries," said Simon Archibald, Ph.D, vice president, chief scientist, Integra LifeSciences. "It's Integra's most innovative and advanced matrix product to come to market in several decades and has the potential to make a significant contribution to patient care."

08:39 EDT ADDvantage renegotiates lines of credit for Telco, Wireless segments - ADDvantage Technologies Group announced that it has renegotiated its lines of credit for its Telco and Wireless business segments, increasing total borrowing capacity and better positioning the Company for anticipated and accelerating growth for both 5G and Telco. ADDvantage converted its collateralized line of credit for its Telco segment to a factoring line, similar to the Wireless factoring line, all with Vast Bank, N.A. As a result: The Company will be able to borrow up to $9 million against Nave receivables and $1.5 million against Triton receivables, replacing the existing line of credit which will be paid off. The existing Fulton factoring line is restructured, modestly reducing borrowing capacity but on more favorable terms related to customer diversity. The net impact will be that overall borrowing capacity is increased from $16.0 million to $19.0 million.

08:37 EDT Bridgeline's Hawksearch chosen by global distributor of biotech supplies - Bridgeline Digital announced that their site search product Hawksearch has been chosen by a global distributor of biotech supplies to grow online revenue. The distributor purchased a 5-year subscription after "seeing how dramatically Hawksearch increased online sales for other distributors in the electrical, medical, and automotive industries with its advanced features," the company said. Ari Kahn, CEO of Bridgeline, says, "Our investments in the B2B distributor market have created a solution that is second to none in helping distributors with large catalogs grow revenue. This market has huge product catalogs with complex inter-product dependencies. Hawksearch understands how to recommend the right products to shoppers to help them purchase all the components they need each time they visit the site."

08:34 EDT Sharps Compliance announces $36M credit facility - Sharps Compliance announced that it has entered into a new $36.0 million credit facility with a commercial bank. The new facility will be available for, working capital and other general corporate purposes and funding for acquisitions. The agreement replaces the Company's $14.0 million existing credit facility.

08:33 EDT Point confirms no delays to SPLASH trial amid lutetium supply interruption - POINT Biopharma affirmed that a recent reactor shutdown in Europe and current geopolitical events concerning Russia and Ukraine have not impacted the Company's trial timelines or the Company's 2022 business outlook. "One of the founding principles of POINT is to have the most robust supply chain in the radiopharmaceutical industry, from neutron to patient." said Dr. Joe McCann, CEO of POINT Biopharma. "The significant challenges with lutetium-177 supply earlier this year due to an unplanned shutdown of a major reactor in Europe provided an opportunity to demonstrate the robustness of our supply chain. Today I am confirming that the shutdown did not have a negative impact on any aspect of our business, validating our focus on supply chain. I am proud of my team's success, and I am looking forward to seeing them continue to make POINT the most dependable radiopharmaceutical partner of physicians and patients globally." POINT's management team has long-standing relationships with leading external partners for lutetium-177 supply, with each partner having their own diverse networks for neutron irradiation, minimizing the impact of single reactor outages. Establishing redundancy across every key business area is a pillar of POINT's value proposition to physicians and patients, as it is not possible to forecast reactor-related irradiation shortages and other similar radiopharmaceutical supply chain disruptions. Recruitment continues for the Company's Phase 3 SPLASH trial evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer, currently enrolling patients across 32 sites in North America and Europe. Site activations in all jurisdictions remain ongoing to expedite accrual, and the Company continues to expect to report top line data from SPLASH mid-2023.

08:32 EDT Palisade Bio receives FDA 'Study May Proceed' letter for Phase 3 trial of LB1148 - Palisade Bio announced that the Company received a "Study May Proceed" letter from the U.S. Food and Drug Administration for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery. The trial is designed as a global, multi-centered, randomized, double-blinded, parallel-group, placebo-controlled clinical trial enrolling approximately 600 subjects, and will assess the safety and efficacy of LB1148. All patients enrolled in the trial will be undergoing a scheduled bowel resection surgery that will include either laparotomy or laparoscopic surgical approaches. Palisade Bio intends to initiate the Phase 3 clinical trial in the second half of 2022.

08:29 EDT Apple, WiLAN sign patent licensing agreement settling disputes - Quarterhill (QTRHF) subsidiary Wi-LAN Inc. and WiLAN's subsidiary Polaris Innovations Limited announced a new patent license agreement with Apple (AAPL). The Agreement also includes the settlement and dismissal of all litigation pending between WiLAN and Polaris and Apple in the United States, Canada and Germany. The specific consideration payable under the Agreement and all other terms and conditions are confidential.

08:27 EDT Alibaba up 9.5% to $113.40 after the company expanded its buyback to $25B - Shares of Alibaba are up about 9.5% at $113.40 in pre-market trading. Yesterday evening, the company announced that it was expanding its buyback to $25B from $15B over a two-year period through March 2024.

08:25 EDT CinCor Pharma announces anticipated upcoming milestones - Key Anticipated Upcoming Milestones: BrigHtn: Phase 2 trial for CIN-107 in patients with treatment-resistant hypertension: Enrollment completed - achieved in March 2022 with 275 patients randomized; Topline data expected in second half of 2022. HALO: Phase 2 trial for CIN-107 in patients with uncontrolled hypertension; Topline data expected in second half of 2022. Spark-PA: Phase 2 trial for CIN-107 in patients with primary aldosteronism; Topline data expected in second half of 2023. CKD: Planned Phase 2 trial for CIN-107 in patients with uncontrolled hypertension (uHTN) and chronic kidney disease. First patient expected to be dosed in first half of 2022.

08:24 EDT CinCor Pharma sees cash runway through 2024 - Terry Coelho, Executive Vice President, Chief Financial Officer, and Chief Business Development Officer added, "In addition to our clinical and operational progress, during the past year we raised funding which we believe will allow us to aggressively pursue our strategy and provide a cash runway that we estimate should support our business operations as planned, including our ongoing and currently planned Phase 2 and Phase 3 clinical programs, through 2024. We thank all of our investors for their support, including those who participated on our Series B preferred stock financing that raised $141.9 million in net proceeds in 2021, those who invested as part of our IPO at the start of 2022, and all the investors who have joined us since CinCor became public."

08:23 EDT Pharvaris announces preclinical pharmacological data fror PHA121 - Pharvaris has published pharmacological data for the novel small molecule bradykinin B2-receptor antagonist PHA121 and its active metabolite PHA-022484, in a recent open-access article in International Immunopharmacology and will be published in the April 2022 issue of the journal. The preclinical data demonstrate PHA121 specificity and potency for both recombinant and endogenous B2 receptor, including 20-fold higher potency than icatibant, an approved injectable B2-receptor antagonist. Relative to icatibant, PHA121 exhibited improved intrinsic clearance, which predicted the improved in vivo half-life and oral bioavailability seen in clinical studies to date. This novel small molecule bradykinin B2 receptor antagonist is in clinical development for the treatment and prevention of hereditary angioedema attacks. Early clinical data in healthy participants indicate that PHA121 is orally bioavailable, with rapid absorption, favorable pharmacokinetics, and good tolerance. "To our knowledge, PHA121 is the most potent, and the only oral, small-molecule human bradykinin B2 receptor antagonist that has ever been reported," said Anne Lesage, Ph.D., Chief Early Development Officer of Pharvaris and lead author on the publication. "PHA121 acts as a selective and competitive antagonist of the bradykinin B2 receptor, blocking the effect of elevated bradykinin levels that lead to angioedema. This specificity is shown through large margins of inhibition at other targets. Its high potency allows for oral administration with a small dose, and supports Pharvaris' development of this compound for on-demand and prophylactic treatment of HAE." The dataset in this publication demonstrates the in vitro pharmacological characteristics of PHA121 and its active metabolite, PHA-022484. Both compounds show high affinity for the recombinant human bradykinin B2 receptor. In contractility assays, both PHA121 and PHA-022484 demonstrate potent and reversible B2 antagonist activity. The data support a high degree of selectivity over a wide range of molecular targets, including the bradykinin B1 receptor.

08:20 EDT Phathom Pharmaceuticals appoints Molly Henderson as CFO, CBO - Phathom Pharmaceuticals announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022. Henderson most recently served as CFO of UroGen Pharma (URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease.

08:18 EDT Reservoir Media acquires rights to the catalog of composer Henry Jackman - Reservoir Media announced the acquisition of rights in the catalog of award-winning film score composer Henry Jackman. The deal includes rights in Jackman's entire catalog, including scores for blockbuster feature films like the Captain America franchise, Wreck-It Ralph, Jumanji, and many more.

08:16 EDT Splash Beverage Group inks TapouT distribution agreement with Kalil Bottling - Splash Beverage Group announced an agreement with Arizona-based Kalil Bottling which will significantly expand the distribution of TapouT Sports Performance Drink. Kalil's network covers all of Arizona and extends through several highly populated counties across Utah, Colorado, New Mexico and western Texas. The distribution of Splash products now reaches more than half the country covering major metropolitan centers across major portions of the US.

08:15 EDT Magnite announces addition of two new board members - Magnite (MGNI) announced the addition of two new members to its Board of Directors: Diane Yu and Dave Pearson. Pearson will also join as a member of the Audit Committee. Diane Yu has served as the Chief Technology Officer of Better.com since January 2021. Dave Pearson has served on the Board of Directors of Lee Enterprises (LEE) since February 2020, and is also a member of Lee's Audit Committee.

08:12 EDT Vertex moves VX-147 into clinical development for proteinuric kidney disease - Vertex Pharmaceuticals Incorporated announced that the company has advanced VX-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the APOL1 gene , which affects approximately 100,000 people in the U.S. and Europe. VX-147 is the first investigational therapy aimed at treating the underlying cause of AMKD. The pivotal study will open for enrollment later this month. The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD. The primary endpoint of this study is reduction in the rate of decline of kidney function as measured by estimated glomerular filtration rate slope versus placebo at approximately two years. The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope in VX-147 versus placebo, supported by a percent change from baseline in proteinuria. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD. "VX-147 holds the potential to be a first-in-class and best-in-class treatment for patients with AMKD, based upon Phase 2 results demonstrating a 47.6% reduction in proteinuria in APOL1-mediated focal segmental glomerulosclerosis ," said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. "We are very pleased to have concluded our discussions with the FDA, enabling us to initiate the pivotal development program evaluating VX-147 in the broad patient population with AMKD and to have a clear path forward for potential accelerated approval in the U.S."

08:12 EDT Impel NeuroPharma to present Trudhesa data at 2022 AAN meeting - Impel NeuroPharma announced planned poster presentations at the upcoming American Academy of Neurology annual meeting, to be held April 2 - 7, 2022 in Seattle, Washington. Impel will be presenting additional data from the pivotal, Phase 3 STOP-301 trial exploring the safety and efficacy of INP104, marketed as Trudhesa nasal spray. Using Impel's proprietary POD technology, Trudhesa delivers dihydroergotamine mesylate -a proven, well-established therapeutic for the acute treatment of migraine for adults-quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and reduces potential absorption issues, offering rapid, sustained, and consistent symptom relief without nausea commonly associated with injection or infusion DHE, even when administered hours after the onset of a migraine attack. Impel will present additional data from the pivotal, Phase 3 STOP-301 Trial, looking at the exploratory efficacy of Trudhesa treatment over 24 weeks based on acute medications used prior to Trudhesa. There are many evidence-based migraine acute treatments currently available and these are either migraine non-specific or migraine-specific. Since there are numerous acute therapies available, it is important to determine if the efficacy of Trudhesa is impacted by prior acute treatment history. Acute therapies most commonly used prior to initiation of treatment with Trudhesa treatment initiation were acetaminophen, NSAIDs, and triptans. This analysis suggests that Trudhesa is an effective treatment for migraine patients who have previously used a variety of acute therapies. A second post hoc analysis aimed to determine if early treatment response to Trudhesa could predict response over consecutive migraine attacks. These data found that patients who self-report mild or no pain at two hours for their first three Trudhesa-treated migraine attacks are extremely likely to respond to Trudhesa treatment. Those with no or mild pain for their first two Trudhesa treated migraine attacks were also likely to respond to Trudhesa treatment. Results suggest that if Trudhesa provides pain relief for the first two to three migraine attacks, it is likely a patient will respond to Trudhesa with long-term use, which is informative for clinical decision making. An additional post hoc analysis, from the STOP-301 trial, supports the need for new and effective acute therapies that will rapidly resolve migraine symptoms and provide a sustained benefit to potentially reduce interictal symptoms. The analysis investigated headache-related disability, time between migraine attacks, and frequency of migraine attacks over 24 weeks, which were exploratory outcome measures relevant to interictal burden. The data suggest that repeated acute use of Trudhesa may have positive effects on interictal burden by reducing migraine-associated disability, prolonging the headache-free period, and decreasing the number of migraine attacks over time.

08:10 EDT Troika Media completes acquisition of Converge Direct - Troika Media announced that it has completed the company's previously-announced definitive purchase agreement to acquire Converge Direct and its affiliates. This acquisition marks a significant step forward in TMG's ongoing transformation into a global, end-to-end brand solutions platform, with significant financial benefits. "The addition of Converge adds a highly complementary, market-leading performance marketing portfolio to our already strong business, significantly expanding our scale and reach," said Robert Machinist, Troika's Chairman and CEO. "We continue to be impressed by the depth of talent and value-creation potential of Converge, and will leverage its extensive network, expertise and strong customer relationships to offer a wider range of tailored, innovative solutions to address our clients' digital content, data and digital media needs. Furthermore, we are confident that adding Converge to our portfolio, with its attractive high-growth SaaS platform, is the best way to drive continued long-term growth and accelerate profitability going forward. This is a very exciting day for both companies and we welcome Converge people to the TMG team, and look forward to working together to create more value for our clients, our people, and our shareholders." Converge's management team have entered into long-term Employment Agreements and will take an active leadership role in the combined business. Sid Toama, Chief Operating Officer of Converge, will join Troika's Board of Directors, and serve as President of Troika. Tom Marianacci, Founder and Chief Executive Officer of Converge will remain CEO of the Converge entities and be a board advisor to Troika. Other members of Converge's Executive Leadership Team have also entered into long term employment agreements with Troika.

08:10 EDT BioSig Technologies announces $3M financing with family office - BioSig Technologies announced that it entered in a definitive purchase agreement for the sale of $3 million of the Company's common stock and warrants lead by a family office that has deep expertise in small cap emerging growth investing. The closing of the offering is expected to occur on or about March 23, 2022, subject to the satisfaction of customary closing conditions. Under the terms of the financing agreement, the Company will issue 2,611,739 shares of its common stock at a price of $1.15 per share and warrants to purchase 2,611,739 shares of the Company's common stock at $1.40 per share. BioSig intends to use the net proceeds from the offering to fund working capital and continue commercialization activities related to the PURE EP System. This funding and its existing capital should provide sufficient operating capital for BioSig to execute its current business plan.

08:08 EDT Konica Minolta Healthcare highlights advancements with digital radiography - At the 2022 annual meeting of the American Association of Orthopedic Surgeons, Konica Minolta Healthcare Americas, Inc. will showcase its broad array of orthopedic and musculoskeletal imaging and information management solutions, including the Dynamic Digital Radiography technology. Konica Minolta is committed to furthering clinical research, demonstrating the clinical value and positive impact to patient care of its technologies. At this year's meeting, there are several presentations in the scientific program highlighting clinical use cases of DDR. Eric R. Wagner, MD, Assistant Professor and Director of Upper Extremity Research at Emory University School of Medicine, will be discussing how dynamic radiographic assessment of upper extremities in motion improves the diagnosis of shoulder pathology and postoperative assessment at an Innovation Theater presentation on Wednesday, March 23. Dr. Wagner has been the lead researcher in using DDR to assess shoulder function and has made DDR the standard of care in his practice. He will also discuss how DDR is used to assess and quantify motion for a range of clinical conditions, including rotator cuff tears, adhesive capsulitis, shoulder arthroplasties and arthritis. DDR is the next evolution in X-ray, enabling clinicians to visualize the physiological motion of joints, extremities and the spine as a patient moves through the full range of motion. DDR is not fluoroscopy, it is a series of individual digital images acquired at high speed and low dose on the KDR(R) Advanced U-Arm, a fully automated digital radiography system. In the same study, clinicians can acquire static and dynamic images. The resulting cine loop provides visualization of the dynamic relationship of anatomical structures in a diagnostic-quality view. Konica Minolta will also be featuring the SONIMAGE HS2, an advanced compact ultrasound system optimized for MSK imaging. It is designed to help clinicians address an array of clinical applications in MSK, vascular, pain management, interventional and orthobiologics.

08:07 EDT Toyota North America partners with ChargePoint on public EV charging solutions - In preparation for the launch of its all-new 2023 bZ4X battery electric SUV later this year, Toyota Motor North America (TM) announced it will work with ChargePoint (CHPT) to offer customers home and public EV charging solutions. For home charging, bZ4X customers will have the option to purchase a ChargePoint Home Flex Level 2 charger from participating Toyota dealerships or directly from ChargePoint online. ChargePoint Home Flex is ENERGY STAR certified and Wi-Fi enabled, can be installed indoors or out, comes with a 23-foot charging cable to support different parking configurations and can charge electric vehicles up to nine times faster than a standard outlet. Translated for the bZ4X, the home charger can charge up to 25 miles of range per hour and fully charge the battery when plugged in overnight. To install the ChargePoint Home Flex, Qmerit has been selected to help guide bZ4X customers through the process of locating a certified EV charger installer, offering an initial free quote and additional services to support them all the way through to installation completion.

08:07 EDT Verizon Connect, AWS collaborate on full cloud migration - Verizon Connect (VZ) recently migrated Verizon Connect Reveal, a comprehensive fleet management software platform, entirely to Amazon Web Services, Inc. (AMZN). Verizon Connect, now fully on AWS, utilizes the AWS multiple Availability Zone architecture for solutions that are secure, scalable and reliable, and also enable continued growth for Verizon Connect.

08:06 EDT DLH Infinibyte Cloud achieves FedRAMP authorization - DLH Holdings announced that its Infinibyte Cloud secure data analytics solution has received Federal Risk and Authorization Management Program authorization.

08:05 EDT HubSpot appoints Rob Giglio as Chief Customer Officer - HubSpot announced that Rob Giglio has joined the company as Chief Customer Officer. Giglio joins HubSpot from DocuSign, where he served as Chief Marketing Officer, and previously spent 11 years at Adobe helping to scale the go-to-market function. He will oversee HubSpot's flywheel organization - the marketing, sales, services, and revenue operations teams - to ensure alignment across the front office. As HubSpot's Chief Customer Officer, Giglio will be responsible for leading all teams tasked with driving strategic projects that advance HubSpot's go-to-market motion and creating a streamlined experience across the company's platform. Giglio brings over 20 years of industry experience leading and executing global marketing and sales initiatives. Prior to joining DocuSign, Rob was Senior Vice President, Digital Media Go-to-Market & Sales at Adobe, where he was responsible for Adobe's Creative Cloud and Document Cloud products and solutions. At Adobe, Rob led the global sales and GTM team of sales, marketing, digital and operations professionals with responsibility for over $7B in revenue. He holds an MBA from the University of Southern California and a B.A. in Psychology from San Diego State University.

08:05 EDT Arteris IP appoints Michal Siwinski as CMO - Arteris IP (AIP) announced that Michal Siwinski has joined the company as its Chief Marketing Officer. He will have worldwide responsibility for all marketing functions and partnership management. As a vital member of the executive team, Mr. Siwinski will report to K. Charles Janac, Arteris IP president and CEO. Siwinski brings more than two decades of B2B technology-based strategy, marketing and growth acceleration from Cadence Design Systems (CDNS). Most recently, he served as its Corporate Vice President of Marketing and Business Development, and through his leadership, the company's brand and digital image was transformed.

08:04 EDT WiMi Hologram Softlight brand obtains Trademark certificate in the U.S. - WiMi Hologram Cloud announced that WIMI's brand WiMi Hologram Softlight has successfully obtained the Trademark registration certificate issued by U.S. Patentand Trademark Office. This trademark will help the company to further improve the intellectual property protection system, maintain the leading position in technology, and enhance the company's core competitiveness.

08:03 EDT Aligos Therapeutics expects cash to fund operations into 1H24

08:02 EDT Kimberly-Clark CFO Maria Henry to retire, Nelson Urdaneta to succeed - Kimberly-Clark (KMB) announced that CFO Maria Henry has decided to retire from the company. She joined Kimberly-Clark as CFO in 2015 and has played a significant role in the design and execution of the company's strategy. Following Kimberly-Clark's earnings call on April 22, Nelson Urdaneta, Senior Vice President, Treasurer at Mondelez International (MDLZ), will succeed Henry as CFO and become a member of Kimberly-Clark's executive leadership team. Urdaneta joins the company after nearly 17 years at Mondelez, where he held numerous positions of increasing responsibility across multiple geographies, including Corporate Controller and Chief Accounting Officer, CFO of Asia Pacific and General Manager of Venezuela.

07:55 EDT Moderna announces new development programs for mRNA pipeline - Moderna announced that it is expanding its mRNA pipeline with two new development programs. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four of the endemic human coronaviruses. First, as part of Moderna's approach to advance a portfolio of respiratory candidates, it is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate is envisioned as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus. Second, Moderna is introducing a program to develop a vaccine candidate against endemic human coronaviruses. While less-well known than other coronaviruses, HCoVs are a significant cause of respiratory disease worldwide. Four HCoVs are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults. Respiratory tract infections are a major public health problem, and these development programs are aimed at the major causative agents. Coronaviruses, seasonal influenza, and RSV take a substantial toll on human health, particularly among older adults who experience more severe illness and greater mortality than younger adults.

07:50 EDT Flyht Aerospace completes acquisiton of CrossConsense - FLYHT Aerospace Solutions announced the closing of the transaction to acquire CrossConsense GmbH & Co. KG, following all required regulatory approvals and the fulfillment of other customary closing conditions. This acquisition is expected to accelerate FLYHT's strategic roadmap to build out a maintenance capability, and fulfill the Company's goal to increase its presence in the European and Middle East markets. Under the terms of the agreement, FLYHT acquired all of the outstanding securities of CrossConsense through its wholly owned German subsidiary formed as part of this transaction.

07:47 EDT Victory Square says Dripbar to become partner on VSDH's white labeled platform - Victory Square Technologies is pleased to announce that The Dripbar will be a new partner company on Victory Square Digital Health's white labeled software technology platform, effective April 1, 2022, to provide The DRIPBaR patients with a seamless and efficient digital health experience, and to support The DRIPBaR's growth and franchise potential. The DRIPBaR have signed up for an initial 5-year term, which will automatically renew unless terminated by either party. VSDH's White Label platform is also being added to The DRIPBaR franchise agreement as the exclusive digital pharmacy and mobile software provider. The pricing model will be a combination of an annual licensing fee, a revenue share on all booking revenue and revenue share on all pharmacy orders. Both VSDH and Hydreight IV will benefit with the revenue stream of this transaction in the form of an annual licensing fee, a percentage of booking revenue and pharmaceutical sales.

07:44 EDT Statera BioPharma announces proposed underwritten public offering - Statera Biopharma announced it has commenced an underwritten public offering. This press release corrects certain deal terms that were in the prior press release. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The proposed offering of the units, consisting of one share of common stock and one one-year warrant to purchase one share of common stock and one five-year warrant to purchase one share of common stock, and pre-funded units, consisting of one pre-funded warrant to purchase one share of common stock and one one-year warrant to purchase one share of common stock and one five-year warrant to purchase one share of common stock, is being offered by the Company pursuant to a "shelf" registration statement on Form S-3 filed with the Securities and Exchange Commission and declared effective by the SEC on May 29, 2020, and the accompanying preliminary prospectus supplement contained therein. Anthony L.G., PLLC is acting as legal counsel to Statera Biopharma, Inc. and Carmel, Milazzo & Feil LLP is acting as legal counsel to EF Hutton for the offering. Bridgeway Capital Partners, LLC is acting as the Company's financial advisor. The offering is being made only by means of a preliminary prospectus supplement and accompanying prospectus. The preliminary prospectus supplement will be filed with the SEC today and a final prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement.

07:41 EDT Wallbridge Mining, Midland resume drilling on gold discovery on Casault - Midland Exploration, in partnership with Wallbridge Mining Company, is pleased to announce the beginning of a new drilling campaign following up on the new gold discovery made in 2021 in the north part of the Casault project. This new discovery was made along a NW-SE-trending structure, approximately 5 kilometres west of the Martiniere gold project held by Wallbridge. The drilling program will begin late March 2022 and will consist of three drill holes totalling approximately 1,100 metres, mainly designed to test the continuity and validate the orientation of the gold zone intersected in discovery hole CAS-21-123. In the latter, an interval grading 6.85 g/t Au over 2.00 metres, from 254.40 to 256.50 metres, was reported during the summer 2021 drilling campaign/ Additional drill holes are being evaluated in the area for future drill programs. During this phase, three drill holes are planned to follow up on hole CAS-21-123. Two holes will be drilled in the immediate vicinity of discovery hole CAS-21-123 and a third hole will be collared approximately 1 kilometre to the southeast, along the same structure. One drill hole totalling 350 metres will be drilled towards the southwest, scissor-style, along the same section as hole CAS-21-123, to test the orientation of veins/intrusions that control gold mineralization. One drill hole totalling 400 metres will be drilled towards the north, to intersect the mineralized zone below hole CAS-21-123 and test the lithological and structural controls of gold mineralization in this area. The final drill hole, totalling 350 metres, will be collared approximately 1 kilometre southeast of the discovery hole and will be drilled towards the northeast, to test the same structure intersected in hole CAS-21-123. The magnetic high observed in this area may indicate the presence of a magnetite-bearing pyroxenite that could have acted as a chemical trap for gold.

07:39 EDT Wesana Health announces data from animal study of psilocybin - Wesana Health Holdings has announced data from an animal study, conducted by an independent global laboratory services provider in a validated model of depression. Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone. Furthermore, a second administration of imipramine given four weeks after a psilocybin loading dose provided an even greater reduction in depressive behaviors. "These results demonstrate that psilocybin has the ability to potentiate the effects of antidepressant medications," said Mark Wingertzahn, Wesana Chief Scientific Officer. "These data could signal a shift in how we develop future clinical treatments for depression using both psilocybin and anti-depressants to optimize outcomes." While there are a number of available therapies to treat depression, only 60%-70% of patients respond to antidepressant therapy. Of those who do not respond, 10%-30% exhibit treatment-resistant symptoms, highlighting the need for additional therapeutic options. Further, despite the established importance of treating depression, only 44% of TBI patients with major depressive disorder received antidepressants or counseling. Of those treated, there is limited evidence supporting the efficacy of antidepressants in the treatment of post-TBI depression3. These new findings suggest that combination therapy could provide more consistent and robust effects over time. Additionally, The Company has entered into an engagement letter with MDM Worldwide for the provision of market awareness and investor relations services. The engagement has a six-month term at a rate of $8,000 per month and upon completion, the issuance of 25,000 Restricted Stock Units.

07:37 EDT Vitalhub enters licensing deal with Buckinghamshire Healthcare NHS Trust - VitalHub is pleased to announce a two-year licensing of subsidiary Intouch with Health's Synopsis solutions to Buckinghamshire Healthcare NHS Trust. This sale marks the 9th Intouch with Health transaction announced this quarter.

07:36 EDT Windtree Therapeutics announces results from Phase 2 study of lucinactant - Windtree Therapeutics announced results from its Phase 2 study of lucinactant for patients with severe COVID-19 associated acute respiratory distress syndrome, ARDS, and lung injury. The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients. The multicenter, single-arm study enrolled 20 critically ill patients who were intubated and on mechanical ventilation due to severe COVID-19 associated ARDS. Patients received lucinactant as a liquid via the endotracheal tube assessing safety and tolerability of the administration procedure and of the drug. Oxygenation and other physiological responses were also measured. Study sites were in the U.S. and Argentina. Key findings from the study were: The trial demonstrated that intratracheal administration of reconstituted lyophilized lucinactant was generally safe and well tolerated and could be safely administered to critically ill, mechanically ventilated patients with severe COVID-19 associated ARDS; Compared to earlier trials in non-COVID-19 ARDS where patients were administered SURFAXIN, it appeared reconstituted lyophilized lucinactant was easier and faster to administer and was associated with fewer peri-dosing side effects that commonly occur when liquid surfactants are administered in the airway; and Oxygenation and other physiological outcomes were generally stable or improved in these critically ill patients; and The results in this study support the feasibility of this treatment approach to develop a potential treatment for critically ill patients with severe ARDS due to COVID-19 or other causes.

07:35 EDT Natera announces publication of study on dd-cfDNA testing using Prospera - Natera announced that a study reporting on the performance of donor-derived cell-free DNA, or dd-cfDNA, testing using the Prospera technology for the assessment of pancreas graft rejection in simultaneous pancreas-kidney, or SPK, transplantation has been published in Transplantation, the official Journal of The Transplantation Society. The study, conducted at the Hospital Clinic of Barcelona, Spain, utilized Prospera technology to detect rejection of a pancreas graft in 36 SPK transplant recipients with pancreas biopsy-matched plasma samples. Pancreas graft status in SPK transplants is currently assessed by non-specific biochemical markers, typically amylase and/or lipase, and confirmed by biopsy. As shown in the study results, the combination of dd-cfDNA donor fraction and quantity reported using Prospera technology outperformed both current biochemical markers and dd-cfDNA donor fraction-alone in assessing pancreas rejection. Dd-cfDNA quantity alone also demonstrated exceptional performance, detecting rejection with a sensitivity of 85.7% and a specificity of 93.7% and achieving an AUC of 0.89 compared to 0.74 for lipase and 0.46 for amylase.

07:33 EDT TriNet announces final results of its modified "Dutch Auction" - TriNet Group announced the final results of its modified "Dutch auction" tender offer to purchase for cash up to $300M in value of its issued and outstanding common stock, par value $0.000025 per share, at a price per share not less than $83.00 and not greater than $97.00, less any applicable withholding taxes and without interest, using available cash on hand. The Tender Offer expired at 12:00 midnight, New York City time, at the end of the day on March 17. The Company's largest stockholder, Atairos Group, did not participate in the Tender Offer. Based on the final count by Computershare Trust Company, the depositary for the Tender Offer, a total of 3,653,690 shares of Common Stock were properly tendered and not properly withdrawn at or below the purchase price of $86.50 per share. In accordance with the terms and conditions of the Tender Offer, TriNet has accepted for purchase 3,653,690 shares at a price of $86.50 per share, for an aggregate cost of approximately $316.0M, excluding fees and expenses relating to the Tender Offer. Included in the 3,653,690 shares that the Company accepted for purchase are 185,482 shares that the Company elected to purchase pursuant to its right to purchase up to an additional 2% of its outstanding shares. The 3,653,690 shares TriNet accepted for purchase represent approximately 5.5% of its outstanding shares as of March 21, 2022. Following the purchase of shares in the Tender Offer, approximately $217M will remain available under the Company's existing stock repurchase program.

07:30 EDT Moderna expands mRNA pipeline with two new development programs - Moderna announced that it is expanding its mRNA pipeline with two new development programs. This announcement reflects the company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four of the endemic human coronaviruses, or HCoV. First, as part of Moderna's approach to advance a portfolio of respiratory candidates, it is launching a respiratory combination vaccine program to target three of the most significant viruses causing respiratory disease in older adults. The new combination respiratory vaccine candidate mRNA-1230 is envisioned as an annual booster targeting SARS-CoV-2 virus, influenza virus and respiratory syncytial virus, or RSV. Second, Moderna is introducing a program to develop a vaccine candidate mRNA-1287 against endemic human coronaviruses, or HCoVs. While less-well known than other coronaviruses, HCoVs are a significant cause of respiratory disease worldwide. Four HCoVs are endemic globally, accounting for approximately 10% to 30% of upper respiratory tract infections in adults.

07:29 EDT Jeune Aesthetics announces clinical Phase 1 efficacy data for KB301 - Jeune Aesthetics announced proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301, Jeune Aesthetics' lead candidate for the treatment of aesthetic skin conditions. KB301 is designed to address declining levels of collagen by delivering the human COL3A1 gene to increase production of normal type III collagen at the site of administration. KB301 leverages Krystal's proprietary gene delivery platform to restore protein production and rebuild the underlying extracellular matrix structure. Above the Knee Safety and Efficacy Results: Low dose KB301 was well tolerated by subjects. Subjects were not administered high dose of KB301 above the knee. Adverse events observed were injection site reactions with 100% of the adverse events categorized as mild. The adverse events were transitory and dramatically reduced during follow-on injections. Efficacy at Visit 6 was clinically meaningful across Subject Satisfaction Scores, Blinded Independent Reviewer Assessment, and Mean Change in Skin Thickness: Subject Satisfaction Scores showed a 21.9% responder rate difference between KB301 and placebo; Blinded Independent Reviewer Assessment showed a 21.5% response rate difference; and The Mean Change in Skin Thickness was 1.07mm between KB301 and placebo Lower Cheek Safety and Efficacy Results: Both the high and the low dose of KB301 were well tolerated by subjects. Adverse events were injection site reactions with 91% of the adverse events categorized as mild and 9% moderate. The adverse events were transitory and dramatically reduced during follow-on injections. Efficacy at Visit 6 was clinically meaningful across Subject Satisfaction Scores and before - after pictures: Subject Satisfaction Scores demonstrated a mean clinical score change of 1.0 between active and placebo for KB301 high dose. The mean score change from baseline to Visit 6 was 1.9 for KB301 and 0.9 for placebo; Before and after picture evaluations showed clear improvement in both fine lines and skin texture in patients administered with high dose KB301; and Blinded independent reviewer assessments using Jeune's Skin Roughness Score and Fine Lines Score did not show clinical separation between active and placebo. These scales, developed specifically for this skin area, will be adapted specifically for KB301 by Jeune Aesthetics prior to advancing development. Upper Cheek Results: Low dose KB301 was well tolerated by subjects. Subjects were not administered high dose of KB301 in the upper cheek. Adverse events were injection site reactions with 98% of the adverse events categorized as mild and 2% moderate. The adverse events were transitory and dramatically reduced during follow-on injections. Efficacy at Visit 6 was clinically meaningful across Subject Satisfaction Scores and before - after pictures: Subject Satisfaction Scores demonstrated a mean clinical score change of 0.6 between active and placebo for KB301 low dose. The mean score change from baseline to Visit 6 was 1.3 for KB301 and 0.7 for placebo; Before and after picture evaluations showed clear improvement in both fine lines and texture in patients administered with low dose of KB301; and Blinded independent reviewer assessments using JASRS and JAFLS did not show clinical separation between active and placebo. These scales, developed specifically for this skin area, will be further developed, validated, and adapted by Jeune Aesthetics specifically for KB301 prior to advancing development. Subjects from the PEARL-1 Cohort 2 trial will be enrolled in a durability trial to look for duration of effect, reduction of the unevenness in placebo treated sites, and for long term safety monitoring. Based on the results from Cohort 2, Jeune Aesthetics is currently planning for two Phase 2a trials - one to improve skin quality attributes in the lower cheek and a second to evaluate the potential of improving the aesthetic appearance in a subject's hand by increasing skin thickness on the back of the subject's hands. A third Phase 2 trial, to evaluate the improvement of skin quality attributes of KB301 in the upper cheek, will be initiated, following development and validation of Jeune Aesthetics' scales in the upper cheek, specific to KB301.

07:21 EDT Else Nutrition launches Toddler Omega complete & balanced nutrition drink - Else Nutrition announces that is it set to launch Else Toddler Omega complete & balanced nutrition drink in the coming weeks on Amazon.com and soon after on the Company's e-store. This will be followed by retail distribution in select retail outlets. The Company has formulated Else Toddler Omega, its first toddler product to have added Omega 3 and Omega 6 fatty acids that support brain and eye development, designed to optimize essential proteins, making it complete and balanced. "We're thrilled to build on the success of our flagship Organic Toddler product, with a new offering that addresses a larger audience. We're continually innovating to respond to customers' requests and pediatricians' expectations, and this offering is expected to further expand the size and growth rate of our Toddler-targeted business," said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition.

07:19 EDT Wellbeing Digital's KGK completes clinical study for Shakeology - Wellbeing Digital Sciences (KONEF) is pleased to announce that a clinical study conducted by its wholly owned subsidiary, KGK Science for The Beachbody Company (BODY) regarding its superfood nutrition shake named Shakeology has just been published in the Journal of Nutrition. The objective of the Study was to determine if using Shakeology twice-daily can improve weight loss and metabolic outcomes in otherwise healthy overweight and obese adults. The benefits experienced by people in the study align with many years of the results that Shakeology has delivered to consumers. Accordingly, the people in the Shakeology group lost more weight, saw decreases in cholesterol that were already in the normal range and increases in the metabolic hormone adiponectin than in the placebo group. The Study was a 12-week, randomized, double-blinded and placebo-controlled clinical trial that included a sample of 206 overweight and obese adults from 4 different locations in the US and Canada. Participants in the Study were randomized to consume Shakeology or a calorie-matched placebo 30 minutes before breakfast and lunch, while following a calorie restricted diet for 12 weeks. The primary outcome of the Study was weight loss that was significantly greater in the Shakeology group than in the placebo group. The strengths of the Study included a large sample size and the increased weight loss experienced by subjects over and above the calorie-matched placebo. Greater weight loss indicated that the benefits of Shakeology do not just stem from its calories, but also from its additional ingredients including the protein, fiber, superfood and phytonutrient blends that may contribute to the benefits that people experience with the product. The most novel finding from the Study was the increase in the metabolic hormone, adiponectin, which is produced by adipose tissue in the body and influences how a person's body makes, uses and stores energy.

07:17 EDT Universal Stainless & Alloy announces base increase on bar products - Universal Stainless & Alloy Products announced a base price increase of 3% to 10% on bar products. The increase goes into effect immediately for all new orders. Current material and energy surcharges will remain in effect. Chris Zimmer, Executive Vice President and Chief Commercial Officer, commented, "We are in an environment that has brought sharp inflationary cost increases to nearly all areas of our business, and it is necessary for us to adjust our pricing to keep up with this higher cost burden. We will continue to take the actions necessary to manage our organization and maintain our class leading customer service levels and exceptional production quality standard."

07:16 EDT Farmland Partners acquires corn and soybean farm in Edgar County, IL for $910K - Farmland Partners yesterday further expanded its presence in Illinois with the acquisition of a corn and soybean farm in Edgar County. The 65-acre property, which is all tillable, was purchased for $910,000 and will be leased back to the seller for the remainder of the year. "This tract adjoins other farmland owned by the Company, and its addition should enable us to lease a large swath of nearly contiguous land at a premium rental rate in the future," said FPI Chairman and CEO Paul Pittman. "That dynamic improves the tract's income-producing potential and its overall value." FPI now owns approximately 1,180 acres of high-quality farmland around the new property. The Company also purchased a 369-acre farm in Rock Island County, Illinois, on March 18. It now owns 187 farms in the state, spanning 38,212 acres across 20 counties. Pittman noted that FPI has a strong pipeline in place and should close on additional properties soon.

07:14 EDT Cellebrite expands partnership with one of largest sheriff offices in US - Cellebrite announced that it has expanded its strategic, multi-year partnership with one of the largest sheriff's offices in the United States, and a member of the Major County Sheriffs of America Association. "We expect that the agreement will extend the agency's capabilities by helping to accelerate investigations focused on violent crimes and internet crimes against children, ICAC," the company said. Under this agreement, the customer plans to strengthen efforts to collect and review digital evidence by decentralizing capabilities and making them available across the investigative team. The agreement includes an expanded suite of solutions from Cellebrite's end-to-end DI Platform, comprised of Cellebrite Premium Enterprise, Cellebrite UFED, and Physical Analyzer. Additionally, the customer has an active proof-of-concept of Cellebrite Guardian, which is part of its efforts to explore ways to improve how digital evidence is stored, managed, and shared across the investigative team. Alon Klomek, Cellebrite's Chief Business Officer, commented: "Expanding our relationship with a key strategic partner, who is also an early adopter of our solutions, underscores the importance of Cellebrite's entire end-to-end Digital Intelligence platform to law enforcement agencies as they work to accelerate justice and save lives. We are thrilled to further strengthen this relationship and look forward to continuing to work alongside progressive law enforcement agencies to further their investigative capabilities."

07:12 EDT ObsEva announces additional efficacy results for linzagolix - ObsEva announced additional efficacy results from the Phase 3 EDELWEISS 3 trial of linzagolix, an oral GnRH antagonist, in women with moderate-to-severe endometriosis-associated pain, EAP. The results build upon the positive topline results announced in January 2022. Two dose regimens were tested, a 200 mg once-daily dose of linzagolix in combination with hormonal add-back therapy, ABT, and a 75 mg dose of linzagolix without ABT. The co-primary efficacy endpoints were reduction in dysmenorrhea, DYS, and non-menstrual pelvic pain, NMPP, at 3 months. The average reduction of DYS and NMPP at each month up to 6 months are shown in Figure 1. Both DYS and NMPP showed rapid reductions compared to placebo, with continued reduction up to 6 months of treatment and with higher reductions with linzagolix 200 mg + ABT compared to linzagolix 75 mg. A similar pattern was seen for the secondary endpoints of dyschezia and worst pelvic pain. The reductions in endometriosis pain were associated with improvements in quality of life and a reduction in physician and patient intentions to undergo surgery for endometriosis. "These additional results from the EDELWEISS 3 trial provide further promising evidence of linzagolix's potential to be the only approved GnRH antagonist offering an effective once daily oral treatment with and without additional hormonal add-back therapy for women suffering from endometriosis and uterine fibroids," said Brian O'Callaghan, CEO of ObsEva. "We look forward to further development of linzagolix in the endometriosis indication as we advance our mission of providing flexible treatment options in areas of significant unmet need in women's health."

07:09 EDT Blue Water announces publication supporting S&P vaccine platform - Blue Water Vaccines announced that their licensing partner, Cincinnati Children's Hospital Medical Center, or CCHMC, has published a research paper entitled "Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity" in Nano Research. The company's lead vaccine programs are focused on developing transformational and novel vaccines against various infectious diseases, including influenza and gastroenteritis by norovirus or rotavirus infection. "This latest publication highlights the versatility of the S&P platform beyond norovirus / rotavirus application and supports BWV's exploration of utilizing the novel S&P platform to develop vaccine candidates against H1, H3, and Flu B infections," the company said. The research describes new technology developed to generate a unique HA1 norovirus based PVNP that displays the receptor-binding HA1 antigens of influenza viruses. "This study is a great step forward for our S&P platform to develop novel vaccines across a wide range of infections, including influenza and gastroenteritis, which both represent significant global health burdens that need effective management through improved vaccines," said Joseph Hernandez, CEO of BWV. "With our partner at CCHMC, we look forward to the next stage of development of this novel platform and exploration of various vaccine development applications."

07:09 EDT Tilt appoints Lynn Ricci as VP, investor relations, corporate communications - TILT Holdings (TLLTF) announced the Company expanded its leadership team by hiring Lynn Ricci as VP Investor Relations and Corporate Communications. Prior to joining TILT, Ms. Ricci was head of investor relations and communications and led ESG and DEI initiatives at Trulieve Cannabis (TCNNF).

07:07 EDT Chicago Atlantic board increases quarterly cash dividend 53.8% to 40c per share - On March 21, 2022, the Board of Directors increased the regular quarterly cash dividend by 53.8% to $0.40 per outstanding share of common stock, payable on April 14, 2022 to common stockholders of record on March 31, 2022

07:04 EDT Glory Star New Media forms special committee to evaluate proposal letter - Glory Star New Media announced that its Board of Directors has formed a special committee consisting of two independent directors, Ke Chen and Ming Shu Leung, to evaluate and consider the previously announced preliminary non-binding proposal letter dated March 13. Ke Chen will be the chair of the special committee. The Board of Directors cautions the company's shareholders and others considering trading in its securities that no decisions have been made with respect to the company's response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed or that this or any other transaction will be approved or consummated. The company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required by applicable law.

07:03 EDT scPharmaceuticals sees 2022 net loss $43M-$48M - Based on its current operating plan, the Company forecasts its 2022 net loss to be $43 to $48 million. As of December 31, 2021, scPharmaceuticals total shares outstanding was 27,366,707.

07:01 EDT Voyager Therapeutics appoints Sandrock as CEO - Voyager Therapeutics (VYGR) announced the appointment of Alfred Sandrock, Jr., M.D., Ph.D., as chief executive officer, CEO. Dr. Sandrock succeeds Michael Higgins, who served as interim CEO since June 2021, and continues to serve as Chairman of the Voyager Board of Directors. Dr. Sandrock was appointed to the Voyager Board of Directors in February 2022, following 23 years at Biogen (BIIB) where he identified and developed novel therapies for a variety of serious diseases.

06:58 EDT Ferrari announces MoU with Italian intitutions for investments in technology - Ferrari signed a Memorandum of Understanding, or MoU with the Italian Ministry of Economic Development, or MISE), Invitalia, the National Agency for Inward Investment and Economic Development, and the Emilia-Romagna Region. According to the Memorandum of Understanding, the Institutions involved will support Ferrari's plan, which involves investments in technology and production, with a strong focus on innovation as well as a social and environmental commitment. The plan will significantly benefit the territory of Maranello and Modena, and will lead to the employment of 250 new hires. MISE's contribution, under the Development Contract, could reach up to about EUR106M, which will be directed towards industrial projects and research and development activities for new technologies aimed at reducing environmental impact and increasing digitalisation. The Emilia-Romagna Region will also provide complementary funding for investments in research and development, education and environmental protection, as well as support for possible logistical and IT network infrastructure, in collaboration with other local bodies involved. Ferrari will present its industrial plan at the Capital Markets Day, scheduled for 16 June.

06:52 EDT J.Jill sees FY22 CapEx $15M-$18M, up to 10 net store closures

06:46 EDT Canada Goose and Sazaby League to create joint venture in Japan - Canada Goose Holdings and Sazaby League have entered into an agreement to create the joint venture Canada Goose Japan, with plans to accelerate DTC expansion, including retail stores. This agreement will replace an exclusive national distributor arrangement between Sazaby League and Canada Goose. Commencing in April, existing distribution will be assumed by the joint venture, of which each partner will own 50 per cent. Current distribution includes a permanent Canada Goose retail store in Tokyo, a national e-Commerce site, as well as wholesale points of distribution across the country. The new operating model is expected to significantly increase revenue and gross profit per unit from the existing business. Canada Goose Japan is also expected to generate C$60M-C$65M in total revenue in FY23, which is roughly double the contribution from this market in fiscal 2022.

06:33 EDT Dave Inc announces strategic partnership with West Realm Shires Services - Dave Inc. on Monday announced a strategic partnership with West Realm Shires Services, Inc., owner and operator of FTX US, whereby the companies will work together to expand the digital assets ecosystem. FTX Ventures, a $2B venture fund, has also invested $100M in Dave. With this investment, Dave has significantly enhanced its balance sheet with additional resources to expedite its growth strategy and invest in future initiatives, including those crypto-related, the company said in a statement. FTX US will serve as the company's exclusive partner for cryptocurrencies, and the parties are currently exploring ways to introduce digital asset payments into Dave's platform, while continuing to improve the customer experience for Dave members.

06:08 EDT AlphaFlow announces minority equity investment from New York Mortgage Trust - AlphaFlow, a technology platform for institutional investment in real estate debt, announced a minority equity investment from New York Mortgage Trust. AlphaFlow has worked directly with NYMT in recent years to provide NYMT with access to private real estate lenders across the country, particularly in the business purpose loan-space. The investment underscores the strategic focus of AlphaFlow's leadership in delivering institutional-quality products to local lenders. AlphaFlow currently plans to use the new funds to enhance its core product and launch a new financing platform this summer. NYMT is joined by other notable investors in this funding, including Steve Cohen's Point72 Ventures, Rebel Fund, and Gaingels.

06:02 EDT Armada Hoffler CFO Michael O'Hara resigns, Matthew Barnes-Smith to succeed - Armada Hoffler announced that Michael O'Hara, CFO, has resigned his title in preparation for his planned retirement from the company. Concurrently, the Company announced that Matthew Barnes-Smith, the company's Executive Vice President of Finance, who has been mentored by O'Hara for the past 18 months, will assume the CFO role per the company's strategic succession plan. O'Hara has been with the company for 25 years and has been an integral contributor to its success. He will continue with the company through the end of the year with his primary duty being the oversight of the company's major investments at Harbor Point in Baltimore, Maryland, as well as assisting with any remaining transition matters.

05:45 EDT Cloudflare CEO says Okta may have data issue, resetting credentials - Cloudflare (NET) CEO Matthew Prince said via Twitter: "We are resetting the @okta credentials of any employees who've changed their passwords in the last 4 months, out of abundance of caution. We've confirmed no compromise. Okta is one layer of security. Given they may have an issue we're evaluating alternatives for that layer."

05:33 EDT BlackBerry expands collaboration with Marelli in China - BlackBerry announced an expansion of its collaboration in China with Marelli, a Tier 1 global automotive supplier, following previous technology collaboration announcements focused on Digital Cluster developments in 2016 and 2018. Marelli has chosen the BlackBerry QNX Neutrino RTOS and BlackBerry QNX Hypervisor to power their Cockpit Domain Controller, a critical in-vehicle system featuring Infotainment and Digital Cluster functions.

05:26 EDT Halozyme announces data from Argenx ADAPT-SC study achieves primary endpoint - Halozyme (HALO) announced that data from Argenx's (ARGX) Phase 3 ADAPT-SC study evaluating subcutaneous efgartigimod for the treatment of generalized myasthenia gravis, or gMG, achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical non-inferiority to Vyvgart intravenous, or IV, formulation in gMG patients. Based on these results, Argenx has stated it plans to submit a biologics license application, or BLA, to the FDA by the end of 2022.

05:21 EDT Bragg Gaming enters Italian market with Microgame content partnership - Oryx Gaming, a Bragg Gaming company, agreed to distribute content with local Italian operator Microgame. Pursuant to the milestone partnership, Egyptian Magic, the debut title from Bragg's recently launched Atomic Slot Lab studio, will feature in the selection of games made available to local players. In addition, an initial selection of titles from Oryx's content portfolio will go live with Microgame with more games set to follow. Initial exclusive content titles will include Respins of Amun-Re, Golden Nights and Royal Seven, as well as other player favorites. Italy became the first major country in continental Europe to regulate online gambling in 2006 and is now the second largest regulated online market on the continent with expected online casino revenues of $2.3B in 2022, according to H2 Gambling Capital estimates.

05:15 EDT ArcelorMittal establishes strategic partnership with Greenko Group - ArcelorMittal announced it has established a strategic partnership with Greenko Group, India's energy transition company, to develop a 'round the clock' renewable energy project with 975 MW of nominal capacity. The project will combine solar and wind power and be supported by Greenko's hydro pumped storage project, which helps to overcome the intermittent nature of wind and solar power generation. The project will be owned and funded by ArcelorMittal. Greenko will design, construct and operate the renewable energy facilities in Andhra Pradesh, Southern India. Project commissioning is expected by mid-2024. ArcelorMittal's joint venture company in India, ArcelorMittal Nippon Steel India, will enter into a 25 year off-take agreement with ArcelorMittal to purchase 250 MW of renewable electricity annually from the project. This will result in over 20% of the electricity requirement at AM/NS India's Hazira plant coming from renewable sources, reducing carbon emissions by approximately 1.5M tons per year. The project offers AM/NS India the dual benefits of lower electricity costs and lower CO2 emissions, and it also provides an attractive return on investment for ArcelorMittal.

05:09 EDT Nokia extends partnership with T-Mobile Polska - Nokia (NOK) announced that it has extended its partnership with T-Mobile Polska (TMUS) to include the modernization of the operator's existing radio network infrastructure and rollout of 5G services. The move will support T-Mobile Poland's strategy of maintaining technology in the country and delivering services to their customers. Under the ten-year agreement, Nokia will increase its share in T-Mobile's network to 50% with deployment already underway. Nokia will supply T-Mobile Polska with its latest AirScale equipment portfolio including Single RAN, AirScale base stations, and 5G Massive MIMO antennas for indoor and outdoor coverage. T-Mobile Polska plans to utilize 4G and 5G Dynamic Spectrum Sharing on lower bands and later the 3.5 GHz spectrum band for 5G dense urban coverage. This will provide 5G coverage and capacity while simultaneously operating 4G LTE to meet user capacity requirements. Nokia will also provide services, including digital deployment, technical support for operations and maintenance, as well as professional services. Nokia has a partnership with T-Mobile Polska which has included the supply of all radio technologies, particularly the successful expansion of 2G, 3G, 4G, and 5G DSS networks. Nokia has global R&D facilities with thousands of engineers in Wroclaw and Krakow.